Deep vein thrombosis therapeutic methods

Description

TECHNICAL FIELD

This invention relates to monitoring functional parameters of a vessel when an interventional therapy is administered.

BACKGROUND

Deep vein thrombosis (DVT) is a medical condition that results from the formation of a blood clot, or thrombus, within a vein. Thrombi often develop in the calves, legs, or other lower abdomen, but may occur in other vessels. The clot is typically formed from a pooling of blood within the vein due to abnormally long periods of rest, e.g. when an individual is bed ridden following surgery or suffering a debilitating illness. Thrombi are likely to form at the location of a stenosis, an unnatural narrowing of an artery. Other causes of thrombosis include genetic deficiencies, autoimmune disorders, and endothelial cell injury.

The thrombus may partially or completely block blood flow. In some circumstances, the thrombus may break off and travel through the blood stream causing serious health issues. For example, when a thrombus of the lower extremities breaks off, the thrombus may travel through the lungs and cause a pulmonary embolism. A pulmonary embolism is a blockage of the blood supply to the lungs that causes severe hypoxia and cardiac failure. It frequently results in death.

Thrombolysis, also known as thrombolytic therapy, is a procedure that disrupts and eliminates blood clots (such as those causing DVT) within the vasculature. Currently, there are several different thrombolytic treatment procedures. For example, thrombolysis may involve the delivery of pharmaceutical drugs designed to dissolve clots within the bloodstream. The drugs can be intravenously injected or can be delivered directly to the blood clot using a catheter. Other modes of treatment include using interventional catheters with ablative, cutting, or ultrasonic elements that mechanically break-up the blood clot within the vasculature.

Removal of blockages using a catheter (drug delivery or interventional) is a complicated procedure that requires complete dissolution of the blockage to restore blood flow/pressure and reduce re-clotting. Some techniques use angiography to monitor the blockage removal; however, angiogram images alone do not provide enough information to determine whether dissolution is complete.

SUMMARY

Methods of the invention provide for more complete dissolution of thrombi within a vessel than possible using angiography and other external imaging modalities. Aspects of the inventions are accomplished by using a sensing device with one or more functional measurement sensors before, during, and/or after the thrombolytic therapy. In preferred embodiments, the sensing device is a sensing guidewire. By measuring functional parameters (such as pressure and flow) with a sensing guidewire, one is able to continually monitor the thrombolytic procedure because the interventional catheter for removing the thrombi can be driven over the sensing guidewire. In certain embodiments, the sensing device may also include an imaging element.

Methods of the invention may be used to assess and monitor treatment of any stenosis or thrombosis, and are particularly well-suited to assess thrombolysis of clots associated deep vein thrombosis. Because functional flow measurements may be obtained prior to initiation, during, and after thrombolytic treatment, sensing devices of the invention may be used to assess the extent of the blockage, monitor progress of the clot dissolution throughout the procedure, and evaluate the success of the deep vein thrombosis treatment. Specifically, sensing devices, in accordance with the invention, may be used to determine when blood flow and pressure has been re-established, determine the extent to which flow and pressure has been established, guide a clinician to determine if more therapy is needed, determine when therapy is complete, and assess the health of the vessel after treatment.

Sensing devices for use in methods of the invention may include a guidewire, catheter, or other intraluminal device with one or more data collectors for obtaining functional measurements. Typically, the data collector for obtaining functional data is a pressure sensor, flow sensor, or combination thereof. Preferably, the intraluminal device is a guidewire with both a pressure sensor and a flow sensor on a distal portion of the device. Pressure sensors are able to obtain pressure measurements and flow sensors are able to obtain velocity measurements within a blood vessel. The ability to measure and compare both the pressure and flow significantly improves the diagnostic accuracy of ischemic testing.

Functional measurements obtained from the data collectors can include, for example, determinations of pressure and/or flow in the vicinity of a clot. In certain embodiments, functional measurements are obtained proximal and distal to a clot, which can then be compared to discern the extent of the blockage and the success of the treatment. Other suitable functional measurements can involve manipulations of the pressure and/or flow data to arrive at other functional parameters, including without limitation, fractional flow reserve (FFR), instantaneous wave-free ratio (iFR), and coronary flow reserve (CFR).

Methods of the invention may be used to monitor any thrombolytic treatment used to break-up or dissolve blood clots within the vasculature of a patient. The thrombolytic treatment may be non-invasive or invasive. Non-invasive thrombolytic treatment may involve injecting clot-dissolving medications into one's bloodstream. Invasive thrombolytic treatment commonly includes introducing an interventional catheter into the vasculature and mechanically/chemically dissolving the blood clot. Several different types of interventional catheters may be used for thrombolytic treatment, including morcellating catheters, ablative catheters, drug delivery catheters, and ultrasonic catheters. In certain aspects, clot-dissolving medicines are used in combination with any of the above-described interventional catheters to perform thrombolysis.

In addition, methods of the invention may be used to assess and treat clotting associated with multiple sclerosis (MS), pulmonary embolisms, clots associated with ischemic stroke, and clots associated with dialysis bypass grafts. In one series of embodiments, the invention consists of methods and devices for identifying patients whose MS, or MS symptoms, are likely exacerbated if not caused, at least in part, by blockages of one or more of the patient's internal jugular veins (UV) or azygous veins (AZV). In preferred embodiments of the diagnostic methods, the stenoses in the patient's affected veins are identified. In other embodiments of the present diagnostic methods, the nature of such lesions and whether there is a significant disruption of blood pressure or flow, or both, is ascertained.

The invention will be described hereafter in detail with particular reference to the drawings. Throughout this description, like elements, in whatever embodiment described, refer to common elements wherever referred to and referenced by the same reference number. The characteristics, attributes, functions, interrelations ascribed to a particular element in one location apply to that element when referred to by the same reference number in another location unless specifically stated otherwise.

BRIEF DESCRIPTIONS OF THE DRAWINGS

FIG. 1 is a flow chart of a method for treating an occluded vessel according to certain embodiments.

FIG. 2 is a flow chart of another method for treating an occluded vessel according to certain embodiments.

FIG. 3 is a flow chart of an embodiment of the diagnostic method of the present invention.

FIG. 4 is a flow chart of another embodiment of the diagnostic method of the present invention.

FIG. 5 is a flow chart of another embodiment of the diagnostic method of the present invention.

FIG. 6 is a flow chart of another embodiment of the diagnostic method of the present invention.

FIG. 7 is a schematic view of an embodiment of the diagnostic device of the present invention.

FIG. 8 is a flow chart of an embodiment of the therapeutic method of the present invention.

FIG. 9 is a flow chart of an alternate embodiment of the therapeutic method of the present invention.

FIG. 10 is a flow chart of an embodiment of the therapy delivered as the therapeutic method of the present invention.

FIG. 11 is a side cross-sectional schematic view of a device of a therapy that could be applied as the therapy of the any of the therapeutic methods of the present invention.

FIG. 12 is a side cross-sectional schematic view of a device of a therapy that could be applied as the therapy of the any of the therapeutic methods of the present invention.

FIG. 13 is an end schematic view of the device of FIG. 12.

FIG. 14 is a side cross-sectional schematic view of a device of a therapy that could be applied as the therapy of the any of the therapeutic methods of the present invention.

FIG. 15 is a side cross-sectional schematic view of an alternate embodiment of the device of FIG. 14.

FIG. 16 is a side cross-sectional schematic view of a device of a therapy that could be applied as the therapy of the any of the therapeutic methods of the present invention.

FIG. 17 is a schematic view of an embodiment of the therapeutic device of the present invention.

FIG. 18 is a flow chart of another embodiment of the therapeutic method of the present invention.

FIG. 19 is a flow chart of another embodiment of the therapeutic method of the present invention.

FIG. 20 is a flow chart of another embodiment of the therapeutic method of the present invention.

FIG. 21 is a flow chart of another embodiment of the therapeutic method of the present invention.

FIG. 22 is a flow chart of another embodiment of the therapeutic method of the present invention.

FIGS. 23 and 24 illustrate a sensing device suitable for use in methods of the invention.

FIGS. 25 and 26 illustrate a sensor housing of the sensing device of FIGS. 23 and 24.

DETAILED DESCRIPTION

The present invention provides methods for assessing a thrombolytic procedure through the use of functional or physiological parameters. Methods of the invention involve introducing a sensing device into a vessel having a thrombus (and/or stenosis) and using the sensing device to evaluate the thrombus before, during, or after thrombolytic treatment. In some embodiments, the sensing device is used throughout the thrombolytic procedure. Methods of the invention are well suited to monitor the success of deep vein thrombosis treatment, but may also be used to assess thrombolysis of other thrombotic conditions, including multiple sclerosis and stroke ischemia.

Any functional or physiological measurement is useful for practicing the invention. Exemplary physiological parameters include blood pressure or flow (velocity) inside the vasculature within the vicinity of the thrombosis. Pressure, flow, or both are measured at various stages of the thrombolytic procedure near the thrombosis. The pressure and flow measurements may be compared to a reference baseline. The reference baseline may be measurements associated with a normal, healthy population or a reference baseline specific to the individual subject to therapy (e.g., measured pressure/flow levels of the patient prior to the thrombosis). According to methods of the invention, a clinician may use those functional measurements to assess whether the thrombus has dissolved/removed to an extent that normal or acceptable blood flow and pressure has been established.

In certain aspects of the invention, these initial functional measurements may be further processed to determine other clinically relevant measurements, such as Fractional Flow reserve measurements, Coronary Flow reserve measurements, instantaneous wave-free ratio (iFR), combined P-V curves.

Coronary flow reserve is defined as the ratio of maximal coronary flow with hyperemia to normal flow. Coronary flow reserve is based on the principle that blood velocity is proportional to volume flow if the lumen area remains constant. Coronary flow reserve signifies the ability of the myocardium to increase blood flow in response to maximal exercise. A ratio at or above 2 is considered normal. Coronary flow reserve measures the velocity of the flow. The fractional flow reserve is defined as the ratio of maximal blood flow achievable in a thrombotic artery relative to the maximal flow in the same vessel if it were normal. Fractional flow reserve measure pressure differences across a portion of a vessel to determine whether a level of constriction or thrombosis of the vessel will impede oxygen delivery to the heart muscle. In order to obtain FFR, a level of pressure distal to a portion of a vessel under examination can be compared to a level of pressure proximal to a portion of a vessel under examination. When used in methods of the invention, changes in coronary flow reserve or fractional flow reserve within a vessel during thrombolytic procedure are indicative that the clot is being dissolved. The procedure may continue until ideal coronary or fractional flow reserve measurements are obtained, thereby indicating the success of the procedure.

P-V loops provide a framework for understanding cardiac mechanics. Such loops can be generated by real time measurement of pressure and volume within the left ventricle. Several physiologically relevant hemodynamic parameters such as stroke volume, cardiac output, ejection fraction, myocardial contractility, etc. can be determined from these loops. To generate a P-V loop for the left ventricle, the LV pressure is plotted against LV volume at multiple time points during a single cardiac cycle. The presence of a thrombus can alter the curve/shape of P-V loop from a normal P-V loop.

The instantaneous wave-free ratio (iFR) is a vasodilator-free pressure-only measure of the hemodynamic severity of a stenosis or thrombosis comparable to fractional flow reserve (FFR) in diagnostic categorization.

The pressure and velocity measurements, particularly regarding the pressure drop-velocity relationship such as Fractional Flow reserve (FFR), Coronary flow reserve (CFR), iFR, and combined P-V curves, can be used to reveal information about the thrombosis and the thrombolytic proceedure. For example, in use, a functional flow device may be advanced to a location relatively distal to a thrombus. The pressure and/or flow velocity may then be measured for a first time. Then, the device may be advanced to a location relatively proximal to the thrombosis and the pressure and/or flow is measured for a second time. The pressure and flow relationships at these two time points are then compared to assess the current state of the thrombolytic procedure and provide improved guidance for the need to continue with or stop the procedure. The ability to take the pressure and flow measurements at the same location and same time with a combined pressure/flow guidewire, improves the accuracy of these pressure-velocity loops and therefore improves the accuracy of the diagnostic information.

Coronary flow reserve, Fractional flow reserve, iFR, and P-V loops may require measurements taken at different locations in the artery. In order to provide measurements for these parameters, systems and methods of the invention may assess pressure and flow at a first location of the data collector against a second location of the data collector within the vasculature. For example, a first location that is distal to a segment of a vessel under examination and a second location that is proximal to that segment of a vessel.

In order to obtain the physiological data described above, methods of the invention may involve the use of a functional measurement or sensing device. The functional measurement device may be equipped with a pressure sensor, a flow sensor, or any combination thereof. Exemplary functional measurement devices suitable for use in practicing the invention include FloWire Doppler Guidewire and the ComboWire XT Guidewire by Volcano Corporation.

Preferably, the sensing device is a guidewire, although the sensing device may also be a catheter. Sensing guidewires are particularly advantageous because they may remain in the vasculature during the thrombolytic procedure while an interventional catheter is driven (ridden) over the sensing guidewire. In this manner, functional flow measurements may be obtained at the same time the thrombolytic catheter is mechanically (ablation, morcellation, or ultrasonic) and/or chemically (with clot dissolving substances) breaking up the blockage.

Guidewires are described in more detail in reference to FIGS. 23-26. In particular embodiments, a pressure sensor can be mounted on the distal portion of a guidewire. In certain embodiments, the pressure sensor is positioned distal to a compressible and bendable coil segment of the guidewire. This allows the pressure sensor to move along with the along coil segment as bended and away from the longitudinal axis. The pressure sensor can be formed of a crystal semiconductor material having a recess therein and forming a diaphragm bordered by a rim. A reinforcing member is bonded to the crystal and reinforces the rim of the crystal and has a cavity therein underlying the diaphragm and exposed to the diaphragm. A resistor having opposite ends is carried by the crystal and has a portion thereof overlying a portion of the diaphragm. Electrical conductor wires can be connected to opposite ends of the resistor and extend within the flexible elongate member to the proximal portion of the flexible elongate member. Additional details of suitable pressure sensors that may be used with devices of the invention are described in U.S. Pat. No. 6,106,476. U.S. Pat. No. 6,106,476 also describes suitable methods for mounting the pressure sensor 104 within a sensor housing.

A flow sensor can be used to measure blood flow velocity within the vessel, which can be used to assess coronary flow reserve (CFR). The flow sensor can be, for example, an ultrasound transducer, a Doppler flow sensor or any other suitable flow sensor, disposed at or in close proximity to the distal tip of the guidewire. The ultrasound transducer may be any suitable transducer, and may be mounted in the distal end using any conventional method, including the manner described in U.S. Pat. Nos. 5,125,137, 6,551,250 and 5,873,835.

A pressure sensor allows one to obtain pressure measurements within a body lumen. A particular benefit of pressure sensors is that pressure sensors allow one to measure of FFR in vessel. FFR is a comparison of the pressure within a vessel at positions prior to the stenosis and after the stenosis. The level of FFR determines the significance of the stenosis, which allows physicians to more accurately identify clinically relevant stenosis. For example, an FFR measurement above 0.80 indicates normal coronary blood flow and a non-significant occlusion. Another benefit is that a physician can measure the pressure before and after an intraluminal intervention procedure to determine the impact of the procedure.

The acquisition of functional measurements typically involves the insertion of a pressure, flow, or combination guidewire into a blood vessel and measuring pressure and/or flow inside the vessel with the device. In practice, measuring pressure and/or flow inside the vessel may also involve injecting a local anesthetic into the skin to numb the area of the patient prior to surgery. A puncture is then made with a needle in either the femoral artery of the groin or the radial artery in the wrist before the provided guidewire is inserted into the arterial puncture. Once positioned, the guidewire may then be used to measure pressure and/or flow in the vessel.

FIG. 1 provides a flow chart for assessing and treating a thrombus, such as a blood clot located in the deep veins, according to one embodiment. As shown in FIG. 1, the first step includes identifying venous outflow obstruction site(s) 310. Typically, venous obstruction sites, which are the locations of the thrombus and/or stenosis, are identified using an external imaging modality, such as angiogram, fluoroscopy, ultrasound, etc., although internal imaging modalities, such as IVUS or OCT, can also be used. Next in step 310, a sensing device is inserted into the identified obstruction site in order to obtain functional data regarding the severity of the obstruction due to the thrombus or stenosis. Based on the functional data, the thrombolytic procedure may be performed (as indicated in step 330). The functional data may provide guidance as to whether the thrombolytic procedure required to treat the thrombus should be invasive or non-invasive. For example, if the functional data indicates that the thrombus is only partially blocking the vessel, then non-invasive therapy with anticoagulants may be indicated. However, if the functional data indicates that the thrombus is a total occlusion, then thrombolysis with an interventional catheter may be indicated.

FIG. 2 provides a flow chart for assessing and treating a thrombus, such as a blood clot located in the deep veins, according to another embodiment. This embodiment includes steps 310, 320, and 330 of FIG. 1, but also involves monitoring functional data during the thrombolytic therapy. As indicated in FIG. 2, after commencement of interventional therapy (step 330), the method further provides for assessing one or more functional measurements during commencement of the therapy (as in step 340). When the sensing device is a guidewire, the sensing device can obtain the functional measurements without having to remove the interventional catheter because the interventional catheter can be ridden over the sensing guidewire. In addition, when the thrombolysis procedure is non-invasive, the sensing device, whether guidewire or catheter) can remain in the vessel during administration of the thrombolysis medicine. In both cases, the sensing device can obtain functional measurements while the interventional therapy is commencing. In further embodiments, the sensing device can be used to obtain functional measurements between bouts of interventional therapy. Based on the assessment step 340, methods of the invention provide for stopping interventional therapy if the functional measurements indicate that the pressure, flow, and related parameters (e.g. FFR or CFR) are normal or acceptable (as in step 350). Alternatively, methods of the invention provide for continuing interventional therapy if the functional measurements indicate that the pressure, flow and related parameters are not normal or acceptable (as in step 350). In such case, the method repeats steps 330 and 340 until the functional measurements indicate that thrombolytic therapy should stop (as in step 350).

The following describes variations of the framework method for assessing stenosis and/or thrombosis of a vessel outlined in FIG. 1. The variations include specific diagnostic and treatment applications, such as specific ways for identifying the venous outflow obstruction sites and specific types of interventional therapy. While subsequent flow charts state diagnosis and treatment of stenosis, it is understood that the diagnostic and treatment methods described herein are applicable to any obstructions, including thrombus and thrombus caused by stenosis. The interventional therapy for thrombolysis may also be used for angioplasty procedures, as invasive thrombolysis is often the same procedure angioplasty.

FIGS. 3-6 depict variations of diagnosing steps (i.e. identifying step 310 and assessing step 320 of FIGS. 1 and 2) the thrombus or stenosis prior to interventional therapy (step 330 of FIGS. 1 and 2).

In a diagnostic method 26 shown in FIG. 3, the diagnostic method begins at step 36 where venous outflow obstruction sites are identified. A preferred method of identifying these obstruction sites is by sequentially accessing the vasculature by selective venography at each of these sites to confirm or exclude a significant stenosis or flow disruption. For deep vein thrombosis, the lower vasculature will be examined, such as the inferior vena cava and femoral veins. For multiple sclerosis assessment, the superior vena cava and common jugular veins should ideally be assessed first. Venography, which is also called phlebography, involves taking an x-ray of the veins, a venogram, after a special dye is injected via a catheter into the vein of interest. Typically, the dye is injected constantly via a catheter. As a result, a venography is an invasive procedure. Although venography has been a preferred method for selecting sites having significant stenosis or flow disruption, ultrasonography, including duplex ultrasonography, could also be used in the alternative or in addition to identify obstructed outflow sites. Ultrasonography incorporates two elements:

1) Grayscale Ultrasound (e.g., from an IVUS imaging system 2) is used to visualize the structure or architecture of the vein to identify stenoses (cross-sectional narrowing of the vein);

2) Color-Doppler ultrasound imaging (e.g., from Volcano Corporation) is then used to visualize the flow or movement of a blood within the vein; and typically presents both displays on the same screen (“duplex”) to facilitate interpretation.

Where ultrasonography is used, a stenosis having cross-sectional narrowing greater than about 70% is considered worthy of treatment as are blood flow velocities greater than 250 cm/sec (which also indicate a region of narrowing or resistance produced by a major stenosis). Ultrasonography can also be enhanced by tissue characterization such as the virtual histology characterization described above, for example, as part of the s5i™ Imaging System with VH capability sold by Volcano Corporation of San Diego, Calif.

Besides venography and ultrasonography, transcutaneous echography applied to an accessible section of the targeted veins could also be used to identify venous outflow obstruction sites and to confirm or exclude a significant stenosis or flow disruption at those sites. Further, in an embodiment of the invention, radionuclides that bind to proteins specific to fibrin, such as radionuclides bound to insulin-like growth factor (IGF) binding proteins (IGFBPs) are applied intravenously, preferably near where an obstruction is believed to be located, or orally. Then, external detectors such as gamma cameras capture and form images from the detected radiation emitted by the radionuclides that are bound to the proteins of the fibrin. This allows the areas of venous outflow obstruction caused by the buildup of thrombus to be located and to confirm or exclude a significant stenosis or flow disruption at the site. These last two methods have the desirable characteristic of being non-invasive.

In a modification of the invention above where something is bound to proteins specific to fibrin, plasmin, other plasmids or any like substance that dissolves fibrin is bound to the same IGFBP that contains the radionuclide or to an entirely different IGFBP and then delivered to the site of the fibrin as described above. The plasmin, plasmid or other substance that dissolves fibrin in whatever form may be self-activated (i.e., it is active upon delivery) or may be activated by the exposure to either a specific light frequency or by ultrasound at a specific frequency or any like energy source delivered either intravascularly or noninvasively. Where these substances are active by a specific light frequency or by ultrasound at a specific frequency, the light or ultrasound or both may be delivered via the distal optics or transducer, respectively.

Once the venous outflow obstruction sites have been identified by whatever method, the method passes to step 38. In step 38, the nature of the stenotic lesion or thrombosis is assessed. This assessment is preferably accomplished by applying an imaging system such as an IVUS or OCT system or a system having both IVUS and OCT or applying both IVUS and OCT imaging to suspected areas of narrowing or flow disruption to identify intraluminal abnormalities including webs, flaps, inverted or incompetent valves and membranes as well as stenoses caused by plaque or the buildup of fibrin or thrombus. Here, a significant stenosis or thrombosis, of whatever kind, is defined as luminal reduction greater than 50% of the normal venous diameter near the stenosis or thrombosis as obtained during step 36 or a significant flow disruption associated with an intraluminal abnormality noted during the IVUS or OCT imaging of this step 38. An exemplary IVUS system is outlined in FIG. 7.

Both IVUS and OCT will provide vessel information whereby vessel circumference measurements can be made. This will allow the physician to check the lumen narrowing to determine whether such narrowing is significant as defined above (i.e., cross-sectional narrowing greater than about 70% or blood flow velocities greater than 250 cm/sec). In a preferred embodiment of the invention, software is provided on the imaging system 2 to correlate these measurements. Once IVUS or OCT or both IVUS and OCT has been used to assess the nature of the stenotic lesion, the method passes to step 40.

In step 40, the pressure, flow, or related parameters are determined. The functional data is preferably determined using a pressure wire, flow wire or any other sensing device if the suspected significant venous thrombosis, stenosis, or other intraluminal abnormality is confirmed by any of the methods of step 38. Examples of pressure wires are the PrimeWire PRESTIGE™ guide wire, PrimeWire® guide wire and the ComboWire® XT guide wire all made and sold by Volcano Corporation of San Diego, Calif.

A pressure gradient larger than 1-2 mm Hg may indicate the presence of a significant thrombosis. Information on the pressure gradient is preferably but not required to be communicated to the healthcare provider via an IVUS console shown in FIG. 7. The communication in this step 40 may take the form of a message displayed on an IVUS console 4, the modifying of an image of a vascular structure displayed on the console 4 such as by appending a text or color indicator that the patient's physiology at that location on the vessel is such that the patient's pressure gradient exceeds the targeted amount, the communication of the parameter values themselves separately or by any other means well within the skill of one skilled in the art to communicate such values.

In the diagnostic method 26 described above, the listed steps 36-40 were performed in the order given. However, it is within the scope of the invention for steps 38 and 40 to be reversed. In this embodiment of the invention shown in FIG. 4, the diagnostic method 26 has the form of the steps above performed in the following sequential order:

Step 36: Identify venous outflow obstruction sites;

Step 40: Determine pressure gradient across the stenosis or thrombosis; and

Step 38: Assess the nature of the stenotic lesion or thrombosis.

Further, in another embodiment of the diagnostic method 26, the method shown in FIG. 3 could be simplified so that either step 38 or step 40 is done without doing the other so that the method takes the following forms, shown in FIGS. 5 and 6, respectively, of the steps above performed in the following sequential order:

Step 36: Indentify venous outflow obstruction sites; and

Step 38: Assess the nature of the stenotic lesion or thrombosis, and,

Step 36: Indentify venous outflow obstruction sites; and

Step 40: Determine pressure gradient across the stenosis or thrombosis.

As mentioned above, the diagnostic method 26 in all forms assesses has a form of deep vein thrombosis, that are likely amenable to treatment by thrombolytic therapy in the patient's vein and, as a result, has diagnostic value as a diagnostic tool. This diagnostic value occurs in all the embodiments of the diagnostic method 26 described above.

The diagnostic method 26 is typically run as software on a computing device 8 and thus the combination of the computing device 8 and the diagnostic methods 26, as described above, becomes the diagnostic device 28. FIG. 7 shows an embodiment of the diagnostic device 28 where the steps 36-38 are performed on the computing device 8. Although the diagnostic device 28 is preferably operated on a computing device 8, the diagnostic device 28 may also be operated separately on any system having sufficient computing capability to perform the steps of the diagnostic method 26 and be operatively connected to the console 4, computing device 8, characterization application 12 or database 10 or any combination of these. In addition, the diagnostic device 28 may also be an application specific device or hardwired specifically to perform the functions described herein.

The diagnostic device 28, in preferred embodiments, acts according to algorithms described above in connection with the diagnostic method 26. The diagnostic device 28 may be implemented on or may be an adjunct to an imaging system 2. The imaging system 2 may take the form of an intravascular ultrasound (IVUS) imaging system 2 as described above including a console 4, IVUS catheter 6, a computing device 8 comprising a database 10 and a characterization application 12 electrically connected to the database 10 and typically run on the computing device 8. Alternately or in addition, the imaging system 2 may take the form of an optical coherence tomography (OCT) system that also includes a console 4, OCT catheter 6, a computing device 8 comprising a database 10 and a characterization application 12 electrically connected to the database 10 and typically run on the computing device 8.

Although IVUS and OCT systems singly or in combination have been described as the imaging system 2, any imaging system that obtains images of the patient's vascular may be used. Such alternate imaging systems 2 will also typically include a console 4, a catheter 6 appropriate for that imaging system 2, a computing device 8 comprising a database 10 and a characterization application 12 electrically connected to the database 10 and typically run on the computing device 8. Regardless of the imaging system 2, the diagnostic device 28 is adapted to communicate, that is both receive and transmit data and information, with the console 4 or the computing device 8.

Where it has been determined that a patient has a form of deep vein thrombisis that is likely amenable to thrombolytic treatment directed to the thombosis in the patient's vein, it is also desirable to have a tool that, under the physician's control, directs a desired therapy to the stenosis. The therapeutic method 30 and its corresponding therapeutic device 32, as described hereafter, is such a tool.

In one embodiment of the therapeutic method 30 shown in FIG. 8, the diagnostic method 26 is included as a diagnostic precursor to applying a desired therapy. So, the therapeutic method 30 in a preferred embodiment includes a diagnostic method 26 that operates as described above in all the variants of diagnostic method 26. In another embodiment of the therapeutic method 30 shown in FIG. 9, the therapeutic method 30 does not include a diagnostic method 26 but includes only the delivery of a therapy 42 as will be described hereafter.

In the embodiment of the therapeutic method 30 of FIG. 8 including a diagnostic method 26, after the diagnostic steps have been accomplished and it has been determined that a patient's physiology has a stenosis or thrombus, the program passes to step 42. In step 42, a desired therapy is applied to treat the thrombus or stenotic lesion. The therapy applied is preferably one that, as a result of the application of the therapy, produces a reduction of the stenosis or dissolution of the blood clot such that the residual stenosis or thrombus no longer is flow limiting or that a pressure gradient exceeding 1-2 mm Hg is no longer observed or both.

In one embodiment of the therapeutic method 30, the therapy in step 42 is invasive thrombolytic therapy, such as therapy with an interventional catheter. Interventional catheters may be used to mechanically cut (e.g., morcellate) the thrombus or stenosis, ablate the thrombus or stenosis, or dissolve the thrombus or stenosis with ultrasonic energy.

FIG. 10 shows a flow chart of the steps involved in the therapeutic method 30 to accomplish such an invasive thrombolysis procedure. The goal of the thrombolysis procedure will be to restore the venous outflow structure to where it is no longer flow limiting, flow disruption is resolved and pressure gradient is minimal.

In FIG. 10, the thrombolytic therapy is begun at step 44 where the appropriate thrombolytic balloon to be used is determined based on measurements previously made such as during a venogram. It is preferable but not required for the balloon to be a non-compliant balloon that will have a nominal inflated diameter of at least 80% of the normal proximal non-clotted or non-stenosed vein. The benefit of using a non-compliant balloon here is to obtain high pressure to increase the opportunity for compression of the obstruction.

The balloon is preferably a one piece balloon. Such a balloon may, but is not required to be, coated with or exuding a drug such as tissue plasminogen activator, urokinase, streptokinase, collagenace, hepranoids and any other fibrinolytic or direct anti-thrombin drug or drugs or antigens or both that may promote more rapid healing of a vessel.

Further, as mentioned above, the balloon may be a cutting or scoring balloon. A cutting balloon is one that has small blades that are activated (moved outward) by actuation of the balloon. The cutting blades score the fibrin of a lesion, particularly thrombus that is attached to and incorporated into the vein wall, thereby creating space that allows the rest of the fibrin to be compressed into a larger opening by the opening of the balloon. When the appropriate balloon to be used to remove the blockage has been determined, by whatever means, the program then passes to step 46. The scoring balloon is one that scores the thrombus and any plaque circumferentially to dilate the obstructed vessel. Suitable scoring balloons include, for example, the AngioSculpt Scoring Balloon Catheter made and sold by AngioScore Inc. of Fremont, Calif.

At step 46, the patient is loaded with intravenous weight based load of heparin (50-100 U/kg) to confirm an Activated Clotting Time (ACT) of at least 250 as is well understood in the art. After loading the patient with heparin to confirm ACT, the program then passes to step 48.

In step 48, the balloon is placed at the stenosis and inflated as is well understood in the art. After confirmation of the ACT, an exchange length 0.035″ exchange length glide wire is advanced into the proximal vein of interest (before the obstruction) and the non-compliant balloon is placed across the blockage. The balloon is slowly inflated, for example, with one atmosphere per 30 seconds until reaching nominal pressure (e.g., 8-12 atmospheres) to open the stenosis. The dilated balloon is left in place for a clinically significant time as is well understood in the art. After the balloon has been left in place for a clinically significant time, the method then passes to step 50.

In step 50, the balloon is deflated and withdrawn. The balloon is preferably deflated at a moderate rate (e.g., one atmosphere per 15 seconds) and then withdrawn from the patient's vascular by techniques well understood in the art.

FIG. 11 shows a device of another therapy that could be applied as the therapy in step 42. In this embodiment of the therapeutic method 30, an occlusive balloon is shown generally labeled 46. The balloon catheter 52 has a catheter body 54 with a distal end 56, an ultimate distal end 58, a proximal end 60, a central lumen 62, a balloon 64 and a balloon lumen 66. The balloon 64 is located a small distance from the ultimate distal end 58 and the central lumen 62 extends from the proximal end of the balloon catheter 52 to the ultimate distal end 58.

The balloon catheter 52 also has an imaging transducer 14 located at the distal end 56 of the balloon catheter 52. The imaging transducer 14 is preferably an IVUS or OCT imaging transducer that is part of an imaging system 2 such as has been described above that allows the user to identify intravascular stenoses or thrombi. The imaging system 2 may also include so-called virtual histology (VH) technology to help the physician recognize and identify the morphology of tissue, particularly plaque associated with a lesion, in vivo (i.e., the location and composition of plaque in the patient's body).

The following systems for detecting and characterizing plaque and thrombi using IVUS with VH are disclosed in U.S. Pat. No. 6,200,268 entitled “VASCULAR PLAQUE CHARACTERIZATION” issued Mar. 13, 2001 with D. Geoffrey Vince, Barry D. Kuban and Anuja Nair as inventors, U.S. Pat. No. 6,381,350 entitled “INTRAVASCULAR ULTRASONIC ANALYSIS USING ACTIVE CONTOUR METHOD AND SYSTEM” issued Apr. 30, 2002 with Jon D. Klingensmith, D. Geoffrey Vince and Raj Shekhar as inventors, U.S. Pat. No. 7,074,188 entitled “SYSTEM AND METHOD OF CHARACTERIZING VASCULAR TISSUE” issued Jul. 11, 2006 with Anuja Nair, D. Geoffrey Vince, Jon D. Klingensmith and Barry D. Kuban as inventors, U.S. Pat. No. 7,175,597 entitled “NON-INVASIVE TISSUE CHARACTERIZATION SYSTEM AND METHOD” issued Feb. 13, 2007 with D. Geoffrey Vince, Anuja Nair and Jon D. Klingensmith as inventors, U.S. Pat. No. 7,215,802 entitled “SYSTEM AND METHOD FOR VASCULAR BORDER DETECTION” issued May 8, 2007 with Jon D. Klingensmith, Anuja Nair, Barry D. Kuban and D. Geoffrey Vince as inventors, U.S. Pat. No. 7,359,554 entitled “SYSTEM AND METHOD FOR IDENTIFYING A VASCULAR BORDER” issued Apr. 15, 2008 with Jon D. Klingensmith, D. Geoffrey Vince, Anuja Nair and Barry D. Kuban as inventors and U.S. Pat. No. 7,463,759 entitled “SYSTEM AND METHOD FOR VASCULAR BORDER DETECTION” issued Dec. 9, 2008 with Jon D. Klingensmith, Anuja Nair, Barry D. Kuban and D. Geoffrey Vince, as inventors, the teachings of which are hereby incorporated by reference herein in their entirety.

In one embodiment of the present invention, a characterization application of the IVUS system is adapted to receive and store venous characterization data (e.g., tissue type, etc.) that is subsequently utilized to classify the tissue type of a patient. For example, after a venous vessel has been interrogated (e.g., IVUS data has been collected), a histology correlation is prepared. In other words, the venous vessel is dissected or cross-sectioned for histology. In one embodiment of the present invention, the cross-section is marked, for example with one or more sutures, so that the histology can be correlated to a portion of the IVUS image based on the marker(s). The cross-section is then prepared with a fixing and staining process that is well known in the art. The staining process allows a trained clinician to identify a tissue type(s), or a chemical(s) found within (e.g., a chemical corresponding to a particular tissue type, etc.). It should be appreciated that the particular method used to identify or characterize the cross-sectional venous vessel is not a limitation of the present invention. Thus, all identification/characterization methods generally known to those skilled in the art are within the spirit and scope of the present invention.

The identified tissue type or characterization (i.e., characterization data) is then provided to the characterization application for storage and access in future procedures. Accordingly, in some instances the characterization data is stored in a venous tissue characteristic database. It should be appreciated that the data may input to the characterization application and/or database using any suitable input device(s) generally known to those skilled in the art. It should further be appreciated that the term tissue type or characterization, as these terms are used herein, include, but are not limited to, fibrous tissues, fibro-lipidic tissues, calcified necrotic tissues, calcific tissues, collagen compositions, cholesterol, thrombus, compositional structures (e.g., the lumen, the vessel wall, the medial-adventitial boundary, etc.) and all other identifiable characteristics generally known to those skilled in the art.

One method of populating the venous tissue characteristic database begins with collecting IVUS data (i.e., RF backscatter data) from a portion of a venous vessel. This data is then used to create an IVUS image at step. The interrogated portion of the venous vessel is cross-sectioned and a tissue type (or a characterization thereof) is identified. This information (i.e., characterization data) is then transmitted to a computing device (or the equivalent thereof). An image of the cross-sectioned vascular object is created and at least one region of interest is identified (e.g., by an operator). This image is then morphed, if needed, to substantially match it to the initially obtained IVUS image. This may include identifying at least one landmark and applying at least one algorithm (e.g., a morphometric algorithm, a thin plate spline deformation technique, etc.). The region(s) of interest is mapped to the IVUS image and associated IVUS data is identified. Spectral analysis is then performed on the associated IVUS data, and at least one parameter is identified. The at least one parameter and the characterization data are then stored in the database. In one embodiment of the present invention, the at least one parameter is stored such that it is linked to the characterization data. It should be appreciated that the order in which these steps are presented is not intended to limit the present invention. Thus, for example, creating an IVUS image after the vascular object is cross-sectioned is within the spirit and scope of the present invention.

The above-described process is repeated for each tissue component desired to be identified and repeated for each component as many times as desired in order to obtain a more accurate range of signal properties. With the database populated, a tissue type or characteristic can be automatically and accurately identified if the acquired parameters substantially match parameters stored in the database. With the venous tissue characteristic database populated, the characterization application of the IVUS system can then be utilized to receive IVUS data, determine parameters related thereto, and use the venous tissue characteristic parameters stored in the database (i.e., histology data) to identify tissue type(s) or characterization(s) thereof.

The central lumen 62 of the balloon catheter 52 is attached to a source of suction (not shown) at the proximal end 60 of the balloon catheter 52 by means well understood in the art. The distal end 56 of the balloon catheter 52 is advanced in the patient's vein of interest past the lesion but where the balloon 64 is downstream of the obstruction. The balloon 64 is inflated so that it occludes blood flow in the vein. In this configuration, the ultimate distal end 58 is located near the lesion. The suction is activates so that suction is applied at the ultimate distal end 58. Because the ultimate distal end 58 is located in close proximity of the lesion, thrombus will be subject to the suction force and sucked into the balloon catheter to travel through the central lumen 62 to be removed through the proximal end 60.

Another embodiment of a device of another therapy that could be applied as the therapy in step 42 is shown in FIGS. 12 and 13. In this embodiment, a cutting catheter 68 is shown. The cutting catheter 68 has a catheter body 70 with a distal end 72, a proximal end 74, a central lumen 76 through which a guide wire (preferably the sensing guidewire as discussed above) may be passed and an outer surface 78. The cutting catheter 68 includes, but is not limited to, the types disclosed in U.S. Pat. No. 5,421,338 entitled “Acoustic Imaging Catheter and the Like” issued to Robert J. Crowley, Mark A. Hamm and Charles D. Lennox on Jun. 6, 1995; U.S. Pat. No. 6,283,921 entitled “Ultrasonic Visualization and Catheters Therefor” issued to Elvin Leonard Nix, Amit Kumar Som, Martin Terry Rothman and Andrew Robert Pacey on Sep. 4, 2001; U.S. Pat. No. 5,800,450 entitled “Neovascularization Catheter” issued to Banning Gray Lary and Herbert R. Radisch, Jr. on Sep. 1, 1998; U.S. Pat. Nos. 5,507,761 and 5,512,044 both entitled “Embolic Cutting Catheter” issued to Edward Y. Duer on Apr. 16, 1996 and Apr. 30, 1996, respectively; U.S. Pat. No. 5,925,055 entitled “Multimodal Rotary Abrasion and Acoustic Ablation Catheter” issued to Sorin Adrian and Paul Walinsky on Jul. 20, 1999; U.S. Pat. No. 4,917,085 entitled “Drive Cutting Catheter Having a New and Improved Motor” issued to Kevin W. Smith on Apr. 17, 1990 and US Published Patent Application No. 2006111704 entitled “Devices, Systems, and Methods for Energy Assisted Arterio-venous Fistula Creation” filed by Rodney Brenneman, Dean A. Schaefer and J. Christopher Flaherty on Nov. 16, 2005, the teachings of which are incorporated herein in their entirety by reference.

The cutting catheter 68 preferably has an imaging transducer 14 as part of an imaging system 2 located at its distal end 72. Further, the cutting catheter 68 includes cutting blades 80 located on its outer surface 78 near the distal end 72. The cutting blades 80 are preferably anywhere from about 0.5-2 mm in depth and from about 5-20 mm in length although other lengths can be used depending on the vessel that the cutting catheter 68 will be used in. The cutting blades 80 can be spaced radially around the outer surface 78 for cutting or scoring circumferentially or can be spaced on one side of the catheter 68 for selective cutting or scoring. When the catheter 68 is pulled back during an imaging procedure, the cutting blades 80 contact and score thrombus and other substance that is attached to and incorporated into the vein wall. In certain embodiments, after some of the thrombus is removed, the rest of the thrombus and/or atheroma material can be compressed into a larger opening by the opening of the balloon.

Yet another embodiment of a device of another therapy that could be applied as the therapy in step 42 is shown in FIG. 14. In this embodiment, an ablation catheter 82 is shown. Such ablation catheter 82 delivers ablation energy through laser, so-called Radio Frequency Ablation or “RFA”, both ablative and thermal, cryoablation, ultrasound, microwave or other energy sources. Examples of such ablation catheters 80 include, but are not limited to, those disclosed in U.S. Pat. No. 6,245,066 entitled “Ablation Catheter” issued to John Mark Morgan and Andrew David Cunningham on Jun. 12, 2001; U.S. Pat. No. 5,267,954 entitled “Ultra-sound catheter for removing obstructions from tubular anatomical structures such as blood vessels” issued to Henry Nita on Dec. 7, 1993; U.S. Pat. No. 6,325,797 entitled “Ablation Catheter and Method for Isolating a Pulmonary Vein” issued to Mark T. Stewart, William J. Flickinger, David E. Franscischelli, Rahul Mehra and Xiaoyi Min on Dec. 4, 2001; U.S. Pat. No. 6,203,537 entitled “Laser-driven Acoustic Ablation Catheter” issued to Sorin Adrian on Mar. 20, 2001; U.S. Pat. No. 5,427,118 entitled “Ultrasonic Guidewire” issued to John H. Wang, Henry Nita, Timothy C. Mills, and Douglas H. Gesswin on Jun. 27, 1995; U.S. Pat. No. 6,701,176 entitled “Magnetic-resonance-guided imaging, electrophysiology, and ablation” issued to Henry R. Halperin, Ronald D. Berger, Ergin Atalar, Elliot R. McVeigh, Albert Lardo, Hugh Calkins and Joao Lima on Mar. 2, 2004; U.S. Pat. No. 6,231,518 entitled “Intrapericardial electrophysiological procedures” issued to James R. Grabek, Carl M. Beaurline, Cecil C. Schmidt, Lawrence A. Lundeen and Patricia J. Rieger on May 15, 2001; U.S. Pat. No. 6,949,094 entitled “Miniature Refrigeration System for Cryothermal Ablation Catheter” issued to Ran Yaron on Sep. 27, 2005; U.S. Pat. No. 6,592,612 entitled “Method and apparatus for providing heat exchange within a catheter body” issued to Wilfred Samson, Hoa Nguyen, Mike Lee, Brady Esch, Eric Olsen and Jeff Valko on Jul. 15, 2003; U.S. Pat. No. 7,291,146 entitled “Selectable Eccentric Remodeling and/or Ablation of Atherosclerotic Material” issued to Tom A. Steinke, Corbett W. Stone, Stephen O. Ross, Brian S. Kelleher, Raphael M. Michel and Donald H. Koenig on Nov. 6, 2007; U.S. Pat. No. 7,742,795 entitled “Tuned RF energy for Selective Treatment of Atheroma and Other Target Tissues and/or Structures” issued to Corbett W. Stone, Michael F. Hoey, Tom A. Steinke, Raphael M. Michel and Arthur G. Blanck on Jun. 22, 2010; US Published Patent Application Nos. 2003092995 entitled “System and method of positioning implantable medical devices” filed by David L. Thompson on Feb. 28, 2002; 2006184048 entitled “Tissue Visualization and Manipulation System” filed by Vahid Saadat on Oct. 25, 2005; 2010256616 entitled “Recanalizing Occluded Vessels Using Radiofrequency Energy” filed by Osamu Katoh and Wayne Ogata on Apr. 2, 2010, 2008262489 entitled “Thrombus Removal” and filed by Tom A. Steinke on Apr. 23, 2008; 2008125772 entitled “Tuned RF Energy and Electrical Tissue Characterization for Selective Treatment of Target Tissues” filed by Corbett W. Stone, Michael F. Hoey, Tom A. Steinke, Raphael M. Michel, Arthur G. Blanck, Marlene Kay Truesdale and Bret Herscher on Oct. 18, 2007 and 2010125268 entitled “Selective Accumulation of Energy With or Without Knowledge of Tissue Topography” filed by Rolfe Tyson Gustus, Linas Kunstmanas and Arthur G. Blanck on Nov. 12, 2009 and WIPO Published Patent Application No. WO03073950 entitled “Optical Fibre Catheter for Thermal Ablation” filed by Andrea Venturelli on Jan. 27, 2003, the teachings of which are incorporated by reference herein in their entirety. Further examples of RF ablation systems include, but are not limited to ablative systems such as that sold by Halt Medical Inc. of Livermore, Calif. that use the heat energy of radio frequency waves to ablate tissue, those sold by Covidien plc through its Valleylab brand in Boulder, Colo. and the VNUS® RF (radiofrequency) Ablation system sold by AngioDynamics of Latham, N.Y.

The ablation catheter 82 has a catheter body 84 with a distal end 86, a proximal end 88, a central lumen 90 through which a guide wire (such as sensing guidewire discussed above) may be passed, an outer surface 92 and ablation system 94. The ablation catheter 82 preferably has, but is not required to have, an imaging transducer 14 as part of an imaging system 2 located at its distal end 86. As the ablation catheter 82 is advanced to the site of the occlusion, the imaging system 2, if present, helps the physician to locate the occlusion. Once the ablation catheter 82 is located at the lesion, the ablation therapy is applied by the ablation system 94 to ablate the occlusion. The imaging system 2 may be particularly useful in helping the physician apply the ablation therapy and assess the extent of such ablation.

In an alternate embodiment of the device of FIG. 14 shown in FIG. 15, the imaging system 2 is an OCT system and ablation system 94 is combined with the distal optics 22 of the imaging system 2. In a variant of this embodiment, the ablation provided by the ablation system 94 is laser ablation that is supplied to the ablation system 94 from the same light source 20 used by the OCT system to produce the OCT images, typically through optical fibers 24 connecting the light source 20 to the distal optics 22. Although the light source 20 used to produce the OCT images would typically be located remotely from the distal optics 22 supplied light via the optical fibers 24, it is within the scope of the present invention in all embodiments for the light source 20 to be located in close proximity to the distal optics 22. In a variant of this, this same light source 20 provides not only the light needed to produce the OCT images but also the laser light used by the ablation system 94 to do the ablation.

Yet another embodiment of a device of another therapy that could be applied as the therapy in step 42 is shown in FIG. 16. In this embodiment, a therapeutic agent deliver catheter 96 is shown. Such therapeutic agent deliver catheter 96 delivers a therapeutic agent to the lesion to dissolve fibrin or thrombus present at or causing the lesion or otherwise treat the lesion. Examples of such therapeutic agent delivery catheters 92 include, but are not limited to, those disclosed in U.S. Pat. No. 5,135,516 entitled “Lubricious Antithrombogenic Catheters, Guidewires and Coatings” issued to Ronald Sahatjian and Kurt Amplatz on Aug. 4, 1992; U.S. Pat. No. 6,535,764 entitled “Gastric treatment and diagnosis device and method” issued to Mir A. Imran, Olivier K. Colliou, Ted W. Layman, Deepak R. Gandhi and Sharon L. Lake on Mar. 18, 2003; U.S. Pat. No. 5,336,178 entitled “Intravascular Catheter with Infusion Array” issued to Aaron V. Kaplan, James R. Kermode and Enrique J. Klein on Aug. 9, 1994; U.S. Pat. No. 7,063,679 entitled “Intra-aortic Renal Delivery Catheter” issued to Mark Maguire and Richard Geoffrion on Jun. 20, 2006; U.S. Pat. No. 7,292,885 entitled “Mechanical Apparatus and Method for Dilating and Delivering a Therapeutic Agent to a site of Treatment” issued to Neal Scott and Jerome Segal on Nov. 6, 2007; U.S. Pat. No. 6,179,809 entitled “Drug Delivery Catheter with Tip Alignment” issued to Alexander Khairkhahan, Michael J. Horzewski, Stuart D. Harman, Richard L. Mueller and Douglas R. Murphy-Chutorian on Jan. 30, 2001; U.S. Pat. No. 5,419,777 entitled “Catheter for Injecting a Fluid or Medicine” issued to Berthold Hofling on May 30, 1995; U.S. Pat. No. 6,733,474 entitled “Catheter for Tissue dilatation and drug Delivery” issued to Richard S. Kusleika on May 11, 2004; and 2010168714 entitled “Therapeutic Agent Delivery System” filed by Jessica L. Burke, Grant T. Hoffman and Drew P. Lyons, Ellettsville, Ind. 1US) on Feb. 3, 2010; 2010125238 entitled “Iontophoretic Therapeutic Agent Delivery System” filed by Whye-Kei Lye and Kareen Looi on Nov. 7, 2009; 2003032936 entitled “Side-exit Catheter and Method for its Use” filed by Robert J. Lederman on Aug. 10, 2001, the teachings of which are incorporated by reference herein in their entirety. Examples of therapeutic agents that may be delivered to the lesion include, but are not limited to tissue plasminogen activator, urokinase, streptokinase, collagenace, hepranoids and any other fibrinolytic or direct anti-thrombin drug.

The therapeutic agent deliver catheter 96 has a catheter body 98 with a distal end 100, a proximal end 102, a central lumen 104 through which a guide wire (such as sensing guidewire discussed above) may be passed, an outer surface 106, a balloon 108 and a balloon lumen 110. The therapeutic agent deliver catheter 96 preferably has, but is not required to have, an imaging transducer 14 as part of an imaging system 2 located at its distal end 100. The balloon 108 is inflated and deflated via the balloon lumen 110 as is well understood in the art. The balloon 108 delivers the therapeutic agent. The therapeutic agent may coat the balloon 108 so that as the balloon is inflated, the therapeutic agent is brought into contact with a lesion so that the therapeutic agent may be applied to the lesion. Alternately, the balloon 108 may be porous or have slits or other fenestrations to allow therapeutic agent present within the balloon to pass through the pores, slits or other fenestrations to come into contact with the tissue at or near a stenosis. As the therapeutic agent deliver catheter 96 is advanced to the site of the lesion, the imaging system 2, if present, helps the physician to locate the lesion. Once the therapeutic agent deliver catheter 96 is located at the lesion, the therapeutic agent to is applied to the lesion as described above. The imaging system 2 may be particularly useful in helping the physician apply the therapeutic agent and assess the extent of such therapy.

The therapeutic method 30 is also typically run as software on a computing device 8 and thus the combination of the computing device 8 and the therapeutic methods 24, as described above, becomes the therapeutic device 32 (FIG. 17). Although the therapeutic device 32 is preferably operated on a computing device 8, the therapeutic device 32 may also be operated separately on any system having sufficient computing capability to perform the steps of the therapeutic method 30, and diagnostic method 26 if present, and be operatively to the console 4, computing device 8, characterization application 12 or database 10 or any combination of these. In addition, the therapeutic device 32 may also be an application specific device or hardwired specifically to perform the functions described herein.

The therapeutic device 32, in preferred embodiments, acts according to algorithms described above in connection with the therapeutic method 30. The therapeutic device 32 may be implemented on or may be an adjunct to an imaging system 2. The imaging system 2 may take the form of an intravascular ultrasound (IVUS) imaging system 2 as described above including a console 4, IVUS catheter 6, a computing device 8 comprising a database 10 and a characterization application 12 electrically connected to the database 10 and typically run on the computing device 8. Alternately or in addition, the imaging system 2 may take the form of an optical coherence tomography (OCT) system that also includes a console 4, OCT catheter 6, a computing device 8 comprising a database 10 and a characterization application 12 electrically connected to the database 10 and typically run on the computing device 8.

In several embodiments of the invention described herein, the therapy delivery device 26 such as the balloon catheter 52, cutting catheter 68, ablation catheter 82 and therapeutic agent deliver catheter 96 included an imaging transducer 14 as part of an imaging system 2 that allowed the therapy delivery device to be located with respect to the lesion so that the therapy could be most effectively applied. In any of the therapy delivery systems described herein, it is preferable but not required but not required to add an imaging transducer 14 as part of an imaging system 2, typically near the distal end of such therapy delivery devices, to also allow the therapy delivery device to be located with respect to the lesion so that the therapy can be most effectively applied.

In any of the embodiments for administering a therapy described above, it may also be useful to apply embolic protection to prevent pieces of fibrin, thrombus or other tissue dislodged by the application of therapy in step 42 from moving downstream with the blood flow. This will remove unwanted material will move with the blood downstream into the patient's heart and ultimately into the patient's lungs where such material may cause an embolism. Consequently, the use of embolic protection such as the SpiderFX® Embolic Protection Device made and sold by ev3, Inc. of Plymouth, Minn. and the FilterWire EZTM Embolic Protection System for SVG's made and sold by Boston Scientific, Inc. of Natick, Mass. may help prevent the occurrence of such embolisms. The therapeutic method 30 in another embodiment shown in FIG. 18 includes a step 114 so that the program passes from step 42 to step 114. In step 114, intraluminal abnormalities are assessed to see if the therapy of step 42 worked. The intraluminal abnormalities may be assessed (as in step 42) using the sensing guidewire, or by introducing an imaging catheter into vessel being treated.

FIG. 19 illustrates using a sensing guidewire to assess the pressure gradient across the stenosis or thrombosis after the therapy of step 42 has been applied Consequently, after step 42 has been completed, the method passes to step 116. At step 116, the pressure gradient across the stenosis is assessed as described in step 38 to determine, post-therapy, whether adequate blood flow is now present as a result of the therapy of step 42. In addition to assessing pressure gradient and as discussed, other functional measurements can also be assessed such as flow, CFR, and FFR in order to determine whether adequate blood flow has been re-established. A sensing guidewire advantageous allows one to determine whether flow and pressure has been restored to normal or acceptable levels without the need to introduce a separate diagnostic catheter. In addition, the therapeutic catheter can remain in the vessel during assessment, and can apply further treatment if data collected from the sensing guidewire indicates further treatment is necessary.

Further, it may be desirable to assess the nature of the treated vessel post-therapy. Post-therapy may be any time after intervention has concluded, and can be immediately after intervention, days, weeks, or months after intervention. Consequently, in another embodiment of the therapeutic methods 24, as shown in FIG. 20, this assessment of the nature of the treatment site post-therapy is preferably accomplished as step 118 by using the sensing guidewire to measure functional parameters or by applying IVUS or OCT or both IVUS and OCT to the area of the applied therapy in step 42. When using functional measurements to assess the vessel post-therapy, the functional measurements can be compared to a normal or baseline reference to determine whether flow or pressure is presenting at healthy or acceptable levels. In addition, IVUS and OCT can be used to assess the diameter of the vessel after intervention. As discussed above, a significant occlusion (i.e. stenosis, thrombosis, or both) is defined as luminal reduction greater than 50% of normal venous diameter as obtained during step 36 or a significant flow disruption associated with an intraluminal abnormality noted during the IVUS or OCT imaging at step 38. Consequently, a successful therapy occurs when the stenosis now has a luminal reduction less than 50% of normal venous diameter as obtained during step 36 with no significant flow disruption.

Although embodiments of the therapeutic method 30 have been described above in connection with a step 42 with may optionally include either step 116 or 118, an alternate therapeutic method 30 may also include both step 116 and 118 performed in any order.

In addition, if the therapy of step 42 was not sufficient to provide the desired blood flow or the desired reduction of the stenosis, in an additional embodiment of the therapeutic method 30, additional therapy of any of the types described above may be applied as shown in FIG. 21. In certain embodiments, the desired reduction of the stenosis is such that the residual stenosis is less than 75% of the normal proximal diameter of the stenotic vein or that a pressure gradient exceeding 1 mm Hg is no longer observed. In this embodiment of the therapeutic method 30, additional therapy will be performed if these therapy goals are not observed. Consequently, in this embodiment of the therapeutic method 30, if the therapy goals are not met, the program passes from step 42 to step 120 where step 120 is the application of an additional therapy. The therapy of step 120 may be either the reapplication of the same therapy that was applied in step 42 or the application of an entirely new therapy of the types described above. In this embodiment of the therapeutic method 30, steps 114, 116 may also be applied as described in connection with step 42 or applied singly or in combination to step 120.

Further, as shown in FIG. 22, after either step 42 or step 120, additional therapy may also be performed at step 122 on all affected veins using the same techniques described above in step 42 if there are additional affected veins with significant occlusions due to stenosis, thrombosis or both. Further, additional therapies or the reapplication of any of the therapies listed above in connection with steps 42 and 120 may be applied to these additional affected veins.

The present invention has been described in connection with many different diagnostic and therapeutic methods and devices. The present invention also anticipates that more than one diagnostic method and device may be applied or combined into a single method or device. Likewise, the present invention also anticipates that more than one therapeutic method and device may be applied or combined into a single method or device. Further, various permutations and combinations of diagnostic and therapeutic devices may be combined together, each acting according to the descriptions above, into a single method or single device.

As discussed above, methods of the invention for assessing functional flow measurements during an interventional procedure, such as thrombolysis, preferably involve use of a sensing guidewire. Referring now to FIG. 23, FIG. 23 provides a schematic illustration of a sensing guidewire being used during a procedure to assess occlusion (stenosis ro thrombosis) in a patient 622. The patient 622 is shown lying on a bed 623 in a surgical lab. The guide wire 621 is used with apparatus 624 which consists of a cable 626 which connects the guide wire 621 to an interface box 627 as shown or directly to a connected to an instrument such as a computing device (e.g. a laptop, desktop, or tablet computer) or a physiology monitor. Interface box 627 is connected by another cable 628 to a control console 629 which has incorporated as a part thereof a video screen 631 on which a waveform 632 displaying functional measurements may be provided. For example, the ECG measurements may appear as traces 632, 633 and 634.

The guide wire 621 is shown more in detail in FIG. 24 and as shown therein, the guide wire 621 can be constructed utilizing the various constructions as shown in U.S. Pat. Nos. 5,125,137; 5,163,445; 5,174,295; 5,178,159; 5,226,421; and 5,240,437. As disclosed therein, such a guide wire consists of a flexible elongate element 641 having a proximal and distal extremities 642 and 643 and which can be formed of a suitable material such as stainless steel having an outside diameter for example of 0.035″, 0.018″, 0.014″ or less and having a suitable wall thickness as for example, 0.001″ to 0.002″ and conventionally called a “hypotube” having a length of 150-170 centimeters. Where a smaller guide wire is desired, the hypotube 641 can have an exterior diameter of 0.014″ or less. Typically such a guide wire includes a core wire (not shown) of the type disclosed in the above identified patents which extends from the proximal extremity to the distal extremity of the flexible elongate element 641 to provide the desired torsional properties for guide wires (See U.S. Pat. No. 5,163,445, col. 18:40-51) to facilitate steering of the guide wire 621 in the vessel.

A coil spring 646 is provided and is formed of a suitable material such as stainless steel. It has an outside diameter of 0.018″ and is formed from a wire having a diameter of 0.003″. The spring 646 is provided with a proximal extremity 47 which is threaded onto the distal extremity 43 of the flexible elongate member 641. The distal extremity 648 of the coil spring 646 is threaded onto the proximal extremity 649 of an intermediate or transition housing 651 such as disclosed in U.S. Pat. No. 5,174,295, formed of a suitable material such as stainless steel having an outside diameter of 0.018″ and having a suitable wall thickness as for example, 0.001″ to 0.002″. The housing includes one or more sensors, such as pressure sensor or flow sensor (See FIGS. 25-26).

A torquer 666 of the type described in U.S. Pat. No. 5,178,159 is mounted on the proximal extremity 642 of the flexible elongate member 641 for causing a rotation of a guide wire 621 when used in connection with catheterization procedures in a manner well known to those skilled in the art.

The proximal extremity 642 is also provided with a plurality of conducting sleeves (not shown) of the type disclosed in U.S. Pat. No. 5,178,159. In the present invention, one or more additional sleeves can be provided to make connection to the conductors hereinafter described. The proximal extremity 642 of the flexible elongate member is removably disposed within a housing 668 of the type described in U.S. Pat. Nos. 5,178,159, 5,348,481 and 5,358,409 that makes electrical contact with the sleeves on the proximal extremity 642 while permitting rotation of the sleeves and the flexible elongate member 641. The housing 668 carries female receptacles (not shown) which receive the sleeves and which are connected to a cable 671 connected to a connector 672. The connector 672 is connected to another mating connector 673 carried by the cable 626 and connected into the interface box 627.

In addition, FIGS. 25 and 26 show a sensor tip 400 of a guidewire 621 that may be suitable to use with methods of the invention. The combination sensor tip 400 includes a pressure sensor 404 within sensor housing 403, flow sensor 501 (which is an ultrasound transducer) and optionally includes a radiopaque tip coil 405 distal to proximal coil 406. FIG. 26 gives a cross-sectional view through combination sensor tip 400, showing ultrasound transducer 501 disposed therein. The ultrasound transducer 501 may be any suitable transducer, and may be mounted in the distal end using any conventional method, including the manner described in U.S. Pat. No. 5,125,137, which is fully incorporated herein by reference. Conductors (not shown) may be secured to the front and rear sides of the ultrasound transducer 501, and the conductors may extend interiorly to the proximal extremity of a guide wire. The pressure sensor 404 may be of the type described in U.S. Pat. No. 6,106,476, which is fully incorporated herein by reference. For example, the pressure sensor 404 may be comprised of a crystal semiconductor material having a recess therein and forming a diaphragm bordered by a rim. A reinforcing member may be bonded to the crystal to reinforce the rim of the crystal, and may have a cavity therein underlying the diaphragm and exposed to the diaphragm. A resistor having opposite ends may be carried by the crystal and may have a portion thereof overlying a portion of the diaphragm. Leads may be connected to opposite ends of the resistor and extend proximally within the guide wire.

Additional details of suitable pressure sensors that may be used as the pressure sensor 404 are described in U.S. Pat. No. 6,106,476. U.S. Pat. No. 6,106,476 also describes suitable methods for mounting the pressure sensor 404 within the combination sensor tip 400. In one embodiment, the pressure sensor 404 is oriented in a cantilevered position within a sensor housing 403. For example, the sensor housing 403 preferably includes a lumen surrounded by housing walls. When in a cantilevered position, the pressure sensor 404 projects into the lumen of the sensor housing 403 without contacting the walls of the sensor housing 403.

In FIG. 26, ultrasound transducer 501 is illustrated as disposed near distal end 202. One advantage of the sensor housing 403 is that because the sensor housing 403 encloses both the ultrasound transducer 501 and the pressure sensor 404, the need for two separate housings, i.e., one for an ultrasound transducer and one for a pressure sensor, is eliminated. Accordingly, the use of a common sensor housing 403 for the ultrasound transducer 501 and the pressure sensor 404 makes the combination sensor tip 400 easier to manufacture than current designs. In certain embodiments, the distance between the pressure sensor 404 and the flow sensor 501 is 0.5 mm, 1.0 mm, 1.5 mm, or 2.0 mm. The placement of both the ultrasound transducer 501 and the pressure sensor 404 near the distal end of the combination sensor tip 400 increases overall flexibility in a guide wire that incorporates the combination sensor tip 400. For example, a prior art guide wire that includes separate sensors, with the pressure sensor being located substantially proximal from the ultrasound transducer, has a longer relatively rigid area that must be devoted to the pressure and flow sensors, i.e., the distance from the ultrasound transducer to the pressure sensor. The guidewire 621, in contrast, substantially reduces or entirely eliminates the distance between the ultrasound transducer and the pressure sensor, thereby allowing for increased flexibility across this length.

It should be noted that in an alternative embodiment of the combination sensor tip 400 (not shown) both the ultrasound transducer 501 and the pressure sensor 404 may be offset from the distal end of the combination sensor tip 400, such as, e.g., 1.5 cm to 3.0 cm from the distal end, but still located in close proximity to each other relative to prior art designs. Thus, the aforementioned advantages over the prior art design are still achieved.

In an alternative embodiment, the pressure sensor housing includes a tubular member having an opening on the outer wall in communication with the lumen and a tip. The tip is constructed of a solder ball. Alternatively a weld, braze, epoxy or adhesive can be used. The lumen of the housing is counter-bored so that the lumen has a smaller inner diameter at the proximal end of the tubular member. For example, the housing may be constructed in the counter-bore fashion with a 0.010″ inner diameter at the proximal end and a 0.012″ inner diameter at the distal end, with the pressure transducer coaxially housed in the lumen. In addition, a flow sensor may be placed in the sensor tip instead of the weld, braze, epoxy or adhesive to provide a combo sensor tip. The advantage of the counter bore is that the housing is easier to make. The transducer is simply slid into place in the lumen and bonded (adhesive or epoxy) where the sides meet the proximal 0.010″ inner diameter 314. The distal 0.012″ inner diameter allows enough room for the pressure sensitive section of the transducer to be free from any contact with the housing. Because of the counter-bored lumen, there is no ledge that has to be made on the outer wall of the lumen, rather the pressure transducer communicates with the outside via an opening in the outer wall of lumen. Constructions suitable for use with a guidewire of the invention are discussed in U.S. Pub. 2013/0030303 to Ahmed, the contents of which are incorporated by reference.

A radiopaque tip coil 405 may be provided at the proximal end of the combination sensor tip 400. The radiopaque tip coil 405 is coupled to a proximal coil 406, and the proximal coil 406 may be coupled to the elongate tubular member. Another improvement of the present invention over current designs that use separate pressure sensor and ultrasound transducer housings is that the present invention provides a smoother transition from the elongate tubular member to the combination sensor tip 400, i.e., the connection between the radiopaque tip coil 405, the proximal coil 406, and the rest of the guide wire is optimized relative to current designs. Specifically, the transition is smoother and more flexible because of the absence of the housing between the radiopaque tip coil 405 and the proximal coil 406. Current designs generally have a tip coil attached to a pressure sensor housing, which in turn is connected to a proximal coil. The present invention eliminates or greatly reduces the separation between the tip coil and the proximal coil that is required in current devices. Suitable coils for use with the present invention are described in U.S. Pat. No. 6,106,476.

In a preferred embodiment, methods of the invention employ a Doppler guidewire wire sold under the name FLOWIRE by Volcano Corporation, the pressure guidewire sold under the name PRIMEWIRE PRESTIGE by Volcano Corporation, or both. Suitable guidewires are also discussed in U.S. Pat. Nos. 5,125,137, 5,163,445, 5,174,295, 5,178,159, 5,226,421, 5,240,437 and 6,106,476.

In certain embodiments, the sensing device, such as sensing guidewire 621, includes an imaging element. Preferably, the imaging element is an ultrasound transducer, although any other imaging elements can be used. Imaging guidewires are described in, for example, U.S. Pat. No. 7,060,033.

The present invention has been described in connection with certain embodiments, combinations, configurations and relative dimensions. It is to be understood, however, that the description given herein has been given for the purpose of explaining and illustrating the invention and are not intended to limit the scope of the invention. In addition, it is clear than an almost infinite number of minor variations to the form and function of the disclosed invention could be made and also still be within the scope of the invention. Consequently, it is not intended that the invention be limited to the specific embodiments and variants of the invention disclosed. It is to be further understood that changes and modifications to the descriptions given herein will occur to those skilled in the art. Therefore, the scope of the invention should be limited only by the scope of the claims.

References and citations to other documents, such as patents, patent applications, patent publications, journals, books, papers, web contents, have been made throughout this disclosure. All such documents are hereby incorporated herein by reference in their entirety for all purposes.

Claims

1. A method for evaluating an interventional therapy applied to a deep vein thrombosis, the method comprising: receiving, from a sensing device inserted into a vessel having a thrombus therein, one or more functional parameters;assessing the one or more functional parameters within the vessel to guide the interventional therapy for treating the thrombus;providing the interventional therapy for treating the thrombus, the interventional therapy being provided by an interventional catheter arranged over the sensing device; andcontinuously monitoring changes in the one or more functional parameters while the delivery of the interventional therapy is performed to evaluate the interventional therapy, wherein the one or more functional parameters comprise fluid flow.
2. The method of claim 1, wherein the functional parameter comprises a pressure gradient across the thrombus, wherein the assessing comprises determining the pressure gradient across the thrombus, and wherein the interventional therapy is continually applied to the thrombus until the monitoring step indicates that the pressure gradient across the thrombus reaches a reference value.
3. The method of claim 1, wherein the sensing device comprises a guidewire, and wherein the guidewire comprises one or more data collectors selected from the group consisting of a pressure sensor, a flow sensor, an imaging element, and combinations thereof.
4. The method of claim 1, wherein the interventional catheter is an ablation catheter and providing the interventional therapy comprises ablating the thrombus with the ablation catheter.
5. The method of claim 1, wherein the interventional catheter comprises a cutting element; and providing the interventional therapy comprises cutting the thrombus and removing the thrombus with the cutting element.
6. The method of claim 1, wherein the interventional therapy comprises injecting a clot-dissolving substance into the vessel via the interventional catheter.
7. The method of claim 1, wherein the one or more functional parameters comprise at least one of: pressure, coronary flow reserve (CFR), and instantaneous wave-free radio (iFR).
8. The method of claim 1, further comprising the step of stopping the interventional therapy based on the monitoring step.
9. The method of claim 1, further comprising the step of continuing the interventional therapy based on the monitoring step.
10. The method of claim 1, wherein the assessing and monitoring steps comprise measuring the one or more functional parameters with the sensing device; and comparing the measured functional parameters against one or more reference levels.
11. The method of claim 1, wherein the method is performed by a computing device.
12. A method for treating deep vein thrombosis with a sensing guidewire inserted into a vessel having a thrombus therein, the sensing guidewire comprising one or more data collectors located on a distal housing and an interventional catheter arranged over the sensing guidewire, the method comprising: receiving, from the one or more data collectors of the sensing guidewire within the vessel, one or more functional parameters;assessing the one or more functional parameters to thereby guide an interventional therapy for treating the thrombus, the interventional therapy being provided by the interventional catheter while the interventional catheter is arranged over the sensing guidewire; andduring the performance of the interventional therapy being provided by the interventional catheter arranged over the sensing guidewire, continually monitoring, using the sensing guidewire, changes in one or more of the functional parameters so that the interventional therapy continues until the one or more of the functional parameters reaches a reference level, wherein the one or more functional parameters comprise fluid flow.
13. The method of claim 12, wherein the one or more data collectors are selected from the group consisting of a pressure sensor, a flow sensor, an imaging element, and combinations thereof.
14. The method of claim 12, wherein the interventional catheter is an ablation catheter and performance of the interventional therapy comprises ablating the thrombus with the ablation catheter.
15. The method of claim 12, wherein the interventional catheter comprises a cutting element; and performance of the interventional therapy comprises cutting and removing the thrombus with the cutting element.
16. The method of claim 12, wherein the interventional therapy comprises injecting a clot-dissolving substance into the vessel via the interventional catheter.
17. The method of claim 12, wherein the one or more functional parameters comprise at least one of: pressure, coronary flow reserve (CFR), and instantaneous wave-free radio (iFR).
18. The method of claim 12, wherein the interventional therapy continues or stops based on monitored changes in the one or more functional parameters.
19. The method of claim 12, wherein the method is performed by a computing device.
20. The method of claim 12, wherein the functional parameter comprises a pressure gradient across the thrombus, wherein the assessing comprises determining the pressure gradient across the thrombus, and wherein the interventional therapy is continually applied to the thrombus until the monitoring step indicates that the pressure gradient across the thrombus reaches a reference value.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. patent application Ser. No. 13/340,120, filed Dec. 29, 2011, which claims priority to and the benefit of U.S. Provisional Patent Application No. 61/429,058, filed Dec. 31, 2010, which are incorporated by reference in their entireties.

US Referenced Citations (1006)

Number	Name	Date	Kind
3301258	Werner	Jan 1967	A
3617880	Cormack et al.	Nov 1971	A
3789841	Antoshkiw	Feb 1974	A
3841308	Tate	Oct 1974	A
4140364	Yamashita et al.	Feb 1979	A
4274423	Mizuno et al.	Jun 1981	A
4344438	Schultz	Aug 1982	A
4398791	Dorsey	Aug 1983	A
4432370	Hughes et al.	Feb 1984	A
4552554	Gould et al.	Nov 1985	A
4577543	Wilson	Mar 1986	A
4676980	Segal et al.	Jun 1987	A
4682895	Costello	Jul 1987	A
4733665	Palmaz	Mar 1988	A
4744619	Cameron	May 1988	A
4762129	Bonzel	Aug 1988	A
4766386	Oliver et al.	Aug 1988	A
4771774	Simpson et al.	Sep 1988	A
4794931	Yock	Jan 1989	A
4800886	Nestor	Jan 1989	A
4803639	Steele et al.	Feb 1989	A
4816567	Cabilly et al.	Mar 1989	A
4819740	Warrington	Apr 1989	A
4821731	Martinelli et al.	Apr 1989	A
4824435	Giesy et al.	Apr 1989	A
4830023	de Toledo et al.	May 1989	A
4834093	Littleford et al.	May 1989	A
4841977	Griffith et al.	Jun 1989	A
4864578	Proffitt et al.	Sep 1989	A
4873690	Adams	Oct 1989	A
4877314	Kanamori	Oct 1989	A
4887606	Yock et al.	Dec 1989	A
4901731	Millar	Feb 1990	A
4917085	Smith	Apr 1990	A
4917097	Proudian et al.	Apr 1990	A
4928693	Goodin et al.	May 1990	A
4932413	Shockey et al.	Jun 1990	A
4932419	de Toledo	Jun 1990	A
4948229	Soref	Aug 1990	A
4951677	Crowley et al.	Aug 1990	A
4969742	Falk et al.	Nov 1990	A
4987412	Vaitekunas et al.	Jan 1991	A
4993412	Murphy-Chutorian	Feb 1991	A
4998972	Chin et al.	Mar 1991	A
5000185	Yock	Mar 1991	A
5024234	Leary et al.	Jun 1991	A
5025445	Anderson et al.	Jun 1991	A
5032123	Katz et al.	Jul 1991	A
5037169	Chun	Aug 1991	A
5039193	Snow et al.	Aug 1991	A
5040548	Yock	Aug 1991	A
5041108	Fox et al.	Aug 1991	A
5054492	Scribner et al.	Oct 1991	A
5065010	Knute	Nov 1991	A
5065769	de Toledo	Nov 1991	A
5085221	Ingebrigtsen et al.	Feb 1992	A
5095911	Pomeranz	Mar 1992	A
5100424	Jang et al.	Mar 1992	A
5120308	Hess	Jun 1992	A
5125137	Corl et al.	Jun 1992	A
5135486	Eberle et al.	Aug 1992	A
5135516	Sahatjian et al.	Aug 1992	A
5155439	Holmbo et al.	Oct 1992	A
5158548	Lau et al.	Oct 1992	A
5163445	Christian et al.	Nov 1992	A
5167233	Eberle et al.	Dec 1992	A
5174295	Christian et al.	Dec 1992	A
5176141	Bom et al.	Jan 1993	A
5176674	Hofmann	Jan 1993	A
5178159	Christian	Jan 1993	A
5183048	Eberle	Feb 1993	A
5188632	Goldenberg	Feb 1993	A
5201316	Pomeranz et al.	Apr 1993	A
5202745	Sorin et al.	Apr 1993	A
5203779	Muller et al.	Apr 1993	A
5220922	Barany	Jun 1993	A
5224953	Morgentaler	Jul 1993	A
5226421	Frisbie et al.	Jul 1993	A
5240003	Lancee et al.	Aug 1993	A
5240437	Christian	Aug 1993	A
5242460	Klein et al.	Sep 1993	A
5243988	Sieben et al.	Sep 1993	A
5257974	Cox	Nov 1993	A
5266302	Peyman et al.	Nov 1993	A
5267954	Nita	Dec 1993	A
5301001	Murphy et al.	Apr 1994	A
5312425	Evans et al.	May 1994	A
5313949	Yock	May 1994	A
5313957	Little	May 1994	A
5319492	Dorn et al.	Jun 1994	A
5321501	Swanson et al.	Jun 1994	A
5325198	Hartley et al.	Jun 1994	A
5336178	Kaplan et al.	Aug 1994	A
5346689	Peyman et al.	Sep 1994	A
5348017	Thornton et al.	Sep 1994	A
5348481	Ortiz	Sep 1994	A
5353798	Sieben	Oct 1994	A
5358409	Obara	Oct 1994	A
5358478	Thompson et al.	Oct 1994	A
5368037	Eberle et al.	Nov 1994	A
5373845	Gardineer et al.	Dec 1994	A
5373849	Maroney et al.	Dec 1994	A
5375602	Lancee et al.	Dec 1994	A
5377682	Ueno et al.	Jan 1995	A
5383853	Jung et al.	Jan 1995	A
5387193	Miraki	Feb 1995	A
5396328	Jestel et al.	Mar 1995	A
5397355	Marin et al.	Mar 1995	A
5405377	Cragg	Apr 1995	A
5411016	Kume et al.	May 1995	A
5419777	Hofling	May 1995	A
5421338	Crowley et al.	Jun 1995	A
5423806	Dale et al.	Jun 1995	A
5427118	Nita et al.	Jun 1995	A
5431673	Summers et al.	Jul 1995	A
5436759	Dijaili et al.	Jul 1995	A
5439139	Brovelli	Aug 1995	A
5443457	Ginn et al.	Aug 1995	A
5453575	O'Donnell et al.	Sep 1995	A
5456693	Conston et al.	Oct 1995	A
5459570	Swanson et al.	Oct 1995	A
5480388	Zadini et al.	Jan 1996	A
5485845	Verdonk et al.	Jan 1996	A
5492125	Kim et al.	Feb 1996	A
5496997	Pope	Mar 1996	A
5507761	Duer	Apr 1996	A
5512044	Duer	Apr 1996	A
5514128	Hillsman et al.	May 1996	A
5529674	Hedgcoth	Jun 1996	A
5541730	Chaney	Jul 1996	A
5546717	Penczak et al.	Aug 1996	A
5546948	Hamm et al.	Aug 1996	A
5565332	Hoogenboom et al.	Oct 1996	A
5573520	Schwartz et al.	Nov 1996	A
5581638	Givens et al.	Dec 1996	A
5586054	Jensen et al.	Dec 1996	A
5592939	Martinelli	Jan 1997	A
5596079	Smith et al.	Jan 1997	A
5598844	Diaz et al.	Feb 1997	A
5609606	O'Boyle	Mar 1997	A
5630806	Inagaki et al.	May 1997	A
5651366	Liang et al.	Jul 1997	A
5660180	Malinowski et al.	Aug 1997	A
5667499	Welch et al.	Sep 1997	A
5667521	Keown	Sep 1997	A
5672877	Liebig et al.	Sep 1997	A
5674232	Halliburton	Oct 1997	A
5693015	Walker et al.	Dec 1997	A
5713848	Dubrul et al.	Feb 1998	A
5745634	Garrett et al.	Apr 1998	A
5771895	Slager	Jun 1998	A
5779731	Leavitt	Jul 1998	A
5780958	Strugach et al.	Jul 1998	A
5798521	Froggatt	Aug 1998	A
5800450	Lary et al.	Sep 1998	A
5803083	Buck et al.	Sep 1998	A
5814061	Osborne et al.	Sep 1998	A
5817025	Alekseev et al.	Oct 1998	A
5820594	Fontirroche et al.	Oct 1998	A
5824520	Mulligan-Kehoe	Oct 1998	A
5827313	Ream	Oct 1998	A
5830222	Makower	Nov 1998	A
5848121	Gupta et al.	Dec 1998	A
5851464	Davila et al.	Dec 1998	A
5857974	Eberle et al.	Jan 1999	A
5872829	Wischmann et al.	Feb 1999	A
5873835	Hastings et al.	Feb 1999	A
5882722	Kydd	Mar 1999	A
5912764	Togino	Jun 1999	A
5916194	Jacobsen et al.	Jun 1999	A
5921931	O'Donnell et al.	Jul 1999	A
5925055	Adrian et al.	Jul 1999	A
5949929	Hamm	Sep 1999	A
5951586	Berg et al.	Sep 1999	A
5974521	Akerib	Oct 1999	A
5976120	Chow et al.	Nov 1999	A
5978391	Das et al.	Nov 1999	A
5997523	Jang	Dec 1999	A
6021240	Murphy et al.	Feb 2000	A
6022319	Willard et al.	Feb 2000	A
6031071	Mandeville et al.	Feb 2000	A
6036889	Kydd	Mar 2000	A
6043883	Leckel et al.	Mar 2000	A
6050949	White et al.	Apr 2000	A
6059738	Stoltze et al.	May 2000	A
6063069	Cragg	May 2000	A
6068638	Makower	May 2000	A
6074362	Jang et al.	Jun 2000	A
6078831	Belef et al.	Jun 2000	A
6080109	Baker et al.	Jun 2000	A
6091496	Hill	Jul 2000	A
6094591	Foltz et al.	Jul 2000	A
6095976	Nachtomy et al.	Aug 2000	A
6097755	Guenther, Jr. et al.	Aug 2000	A
6099471	Torp et al.	Aug 2000	A
6099549	Bosma et al.	Aug 2000	A
6102938	Evans et al.	Aug 2000	A
6106476	Corl et al.	Aug 2000	A
6120445	Grunwald	Sep 2000	A
6123673	Eberle et al.	Sep 2000	A
6134003	Tearney et al.	Oct 2000	A
6139510	Palermo	Oct 2000	A
6141089	Thoma et al.	Oct 2000	A
6146328	Chiao et al.	Nov 2000	A
6148095	Prause et al.	Nov 2000	A
6151433	Dower et al.	Nov 2000	A
6152877	Masters	Nov 2000	A
6152878	Nachtomy et al.	Nov 2000	A
6159225	Makower	Dec 2000	A
6165127	Crowley	Dec 2000	A
6176842	Tachibana et al.	Jan 2001	B1
6179809	Khairkhahan et al.	Jan 2001	B1
6186949	Hatfield et al.	Feb 2001	B1
6190353	Makower et al.	Feb 2001	B1
6200266	Shokrollahi et al.	Mar 2001	B1
6200268	Vince et al.	Mar 2001	B1
6203537	Adrian	Mar 2001	B1
6208415	De Boer et al.	Mar 2001	B1
6210332	Chiao et al.	Apr 2001	B1
6210339	Kiepen et al.	Apr 2001	B1
6212308	Donald	Apr 2001	B1
6231518	Grabek et al.	May 2001	B1
6245066	Morgan et al.	Jun 2001	B1
6249076	Madden et al.	Jun 2001	B1
6254543	Grunwald et al.	Jul 2001	B1
6256090	Chen et al.	Jul 2001	B1
6258052	Milo	Jul 2001	B1
6261246	Pantages et al.	Jul 2001	B1
6275628	Jones et al.	Aug 2001	B1
6283921	Nix et al.	Sep 2001	B1
6283951	Flaherty et al.	Sep 2001	B1
6295308	Zah	Sep 2001	B1
6299622	Snow et al.	Oct 2001	B1
6312384	Chiao	Nov 2001	B1
6325797	Stewart et al.	Dec 2001	B1
6328696	Fraser	Dec 2001	B1
6343168	Murphy et al.	Jan 2002	B1
6343178	Burns et al.	Jan 2002	B1
6350240	Song et al.	Feb 2002	B1
6364841	White et al.	Apr 2002	B1
6366722	Murphy et al.	Apr 2002	B1
6367984	Stephenson et al.	Apr 2002	B1
6373970	Dong et al.	Apr 2002	B1
6375615	Flaherty et al.	Apr 2002	B1
6375618	Chiao et al.	Apr 2002	B1
6375628	Zadno-Azizi et al.	Apr 2002	B1
6376830	Froggatt et al.	Apr 2002	B1
6379352	Reynolds et al.	Apr 2002	B1
6381350	Klingensmith et al.	Apr 2002	B1
6387124	Buscemi et al.	May 2002	B1
6396976	Little et al.	May 2002	B1
6398792	O'Connor	Jun 2002	B1
6417948	Chowdhury et al.	Jul 2002	B1
6419644	White et al.	Jul 2002	B1
6421164	Tearney et al.	Jul 2002	B2
6423012	Kato et al.	Jul 2002	B1
6426796	Pulliam et al.	Jul 2002	B1
6428041	Wohllebe et al.	Aug 2002	B1
6428498	Uflacker	Aug 2002	B2
6429421	Meller et al.	Aug 2002	B1
6440077	Jung et al.	Aug 2002	B1
6443903	White et al.	Sep 2002	B1
6450964	Webler	Sep 2002	B1
6457365	Stephens et al.	Oct 2002	B1
6459844	Pan	Oct 2002	B1
6468290	Weldon et al.	Oct 2002	B1
6475149	Sumanaweera	Nov 2002	B1
6480285	Hill	Nov 2002	B1
6491631	Chiao et al.	Dec 2002	B2
6491636	Chenal et al.	Dec 2002	B2
6501551	Tearney et al.	Dec 2002	B1
6504286	Porat et al.	Jan 2003	B1
6508824	Flaherty et al.	Jan 2003	B1
6514237	Maseda	Feb 2003	B1
6520269	Geiger et al.	Feb 2003	B2
6520677	Iizuka	Feb 2003	B2
6535764	Imran et al.	Mar 2003	B2
6538778	Leckel et al.	Mar 2003	B1
6544217	Gulachenski	Apr 2003	B1
6544230	Flaherty et al.	Apr 2003	B1
6545760	Froggatt et al.	Apr 2003	B1
6546272	MacKinnon et al.	Apr 2003	B1
6551250	Khalil	Apr 2003	B2
6566648	Froggatt	May 2003	B1
6570894	Anderson	May 2003	B2
6572555	White et al.	Jun 2003	B2
6579311	Makower	Jun 2003	B1
6584335	Haar et al.	Jun 2003	B1
6592612	Samson et al.	Jul 2003	B1
6594448	Herman et al.	Jul 2003	B2
6602241	Makower et al.	Aug 2003	B2
6611322	Nakayama et al.	Aug 2003	B1
6611720	Hata et al.	Aug 2003	B2
6612992	Hossack et al.	Sep 2003	B1
6615062	Ryan et al.	Sep 2003	B2
6615072	Izatt et al.	Sep 2003	B1
6621562	Durston	Sep 2003	B2
6631284	Nutt et al.	Oct 2003	B2
6638227	Bae	Oct 2003	B2
6645152	Jung et al.	Nov 2003	B1
6646745	Verma et al.	Nov 2003	B2
6655386	Makower et al.	Dec 2003	B1
6659957	Vardi et al.	Dec 2003	B1
6660024	Flaherty et al.	Dec 2003	B1
6663565	Kawagishi et al.	Dec 2003	B2
6665456	Dave et al.	Dec 2003	B2
6669716	Gilson et al.	Dec 2003	B1
6671055	Wavering et al.	Dec 2003	B1
6673015	Glover et al.	Jan 2004	B1
6673064	Rentrop	Jan 2004	B1
6685648	Flaherty et al.	Feb 2004	B2
6689056	Kilcoyne et al.	Feb 2004	B1
6689144	Gerberding	Feb 2004	B2
6696173	Naundorf et al.	Feb 2004	B1
6701044	Arbore et al.	Mar 2004	B2
6701176	Halperin et al.	Mar 2004	B1
6709444	Makower	Mar 2004	B1
6712836	Berg et al.	Mar 2004	B1
6714703	Lee et al.	Mar 2004	B2
6719717	Johnson et al.	Apr 2004	B1
6725073	Motamedi et al.	Apr 2004	B1
6726677	Flaherty et al.	Apr 2004	B1
6730107	Kelley et al.	May 2004	B2
6733474	Kusleika	May 2004	B2
6738144	Dogariu	May 2004	B1
6740113	Vrba	May 2004	B2
6746464	Makower	Jun 2004	B1
6780157	Stephens et al.	Aug 2004	B2
6795188	Ruck et al.	Sep 2004	B2
6795196	Funakawa	Sep 2004	B2
6798522	Stolte et al.	Sep 2004	B2
6822798	Wu et al.	Nov 2004	B2
6830559	Schock	Dec 2004	B2
6832024	Gerstenberger et al.	Dec 2004	B2
6842639	Winston et al.	Jan 2005	B1
6847449	Bashkansky et al.	Jan 2005	B2
6855115	Fonseca et al.	Feb 2005	B2
6856138	Bohley	Feb 2005	B2
6856400	Froggatt	Feb 2005	B1
6856472	Herman et al.	Feb 2005	B2
6860867	Seward et al.	Mar 2005	B2
6866670	Rabiner et al.	Mar 2005	B2
6878113	Miwa et al.	Apr 2005	B2
6886411	Kjellman et al.	May 2005	B2
6891984	Petersen et al.	May 2005	B2
6895106	Wang et al.	May 2005	B2
6898337	Averett et al.	May 2005	B2
6900897	Froggatt	May 2005	B2
6912051	Jensen	Jun 2005	B2
6916329	Zhao	Jul 2005	B1
6922498	Shah	Jul 2005	B2
6937346	Nebendahl et al.	Aug 2005	B2
6937696	Mostafavi	Aug 2005	B1
6943939	DiJaili et al.	Sep 2005	B1
6947147	Motamedi et al.	Sep 2005	B2
6947787	Webler	Sep 2005	B2
6949094	Yaron	Sep 2005	B2
6952603	Gerber et al.	Oct 2005	B2
6954737	Kalantar et al.	Oct 2005	B2
6958042	Honda	Oct 2005	B2
6961123	Wang et al.	Nov 2005	B1
6966891	Ookubo et al.	Nov 2005	B2
6969293	Thai	Nov 2005	B2
6969395	Eskuri	Nov 2005	B2
6985234	Anderson	Jan 2006	B2
7004963	Wang et al.	Feb 2006	B2
7006231	Ostrovsky et al.	Feb 2006	B2
7010458	Wilt	Mar 2006	B2
7024025	Sathyanarayana	Apr 2006	B2
7027211	Ruffa	Apr 2006	B1
7027743	Tucker et al.	Apr 2006	B1
7033347	Appling	Apr 2006	B2
7035484	Silberberg et al.	Apr 2006	B2
7037269	Nix et al.	May 2006	B2
7042573	Froggatt	May 2006	B2
7044915	White et al.	May 2006	B2
7044964	Jang et al.	May 2006	B2
7048711	Rosenman et al.	May 2006	B2
7049306	Konradi et al.	May 2006	B2
7058239	Singh et al.	Jun 2006	B2
7060033	White et al.	Jun 2006	B2
7060421	Naundorf et al.	Jun 2006	B2
7063679	Maguire et al.	Jun 2006	B2
7068852	Braica	Jun 2006	B2
7074188	Nair et al.	Jul 2006	B2
7095493	Harres	Aug 2006	B2
7110119	Maestle	Sep 2006	B2
7113875	Terashima et al.	Sep 2006	B2
7123777	Rondinelli et al.	Oct 2006	B2
7130054	Ostrovsky et al.	Oct 2006	B2
7139440	Rondinelli et al.	Nov 2006	B2
7153299	Tu et al.	Dec 2006	B1
7171078	Sasaki et al.	Jan 2007	B2
7175597	Vince et al.	Feb 2007	B2
7177491	Dave et al.	Feb 2007	B2
7190464	Alphonse	Mar 2007	B2
7215802	Klingensmith et al.	May 2007	B2
7218811	Shigenaga et al.	May 2007	B2
7236812	Ballerstadt et al.	Jun 2007	B1
7245125	Harer et al.	Jul 2007	B2
7245789	Bates et al.	Jul 2007	B2
7249357	Landman et al.	Jul 2007	B2
7291146	Steinke et al.	Nov 2007	B2
7292715	Furnish	Nov 2007	B2
7292885	Scott et al.	Nov 2007	B2
7294124	Eidenschink	Nov 2007	B2
7300460	Levine et al.	Nov 2007	B2
7335161	Von Arx et al.	Feb 2008	B2
7337079	Park et al.	Feb 2008	B2
7355716	de Boer et al.	Apr 2008	B2
7356367	Liang et al.	Apr 2008	B2
7358921	Snyder et al.	Apr 2008	B2
7359062	Chen et al.	Apr 2008	B2
7359554	Klingensmith et al.	Apr 2008	B2
7363927	Ravikumar	Apr 2008	B2
7366376	Shishkov et al.	Apr 2008	B2
7382949	Bouma et al.	Jun 2008	B2
7387636	Cohn et al.	Jun 2008	B2
7391520	Zhou et al.	Jun 2008	B2
7397935	Kimmel et al.	Jul 2008	B2
7399095	Rondinelli	Jul 2008	B2
7408648	Kleen et al.	Aug 2008	B2
7414779	Huber et al.	Aug 2008	B2
7440087	Froggatt et al.	Oct 2008	B2
7447388	Bates et al.	Nov 2008	B2
7449821	Dausch	Nov 2008	B2
7450165	Ahiska	Nov 2008	B2
RE40608	Glover et al.	Dec 2008	E
7458967	Appling et al.	Dec 2008	B2
7463362	Lasker et al.	Dec 2008	B2
7463759	Klingensmith et al.	Dec 2008	B2
7491226	Palmaz et al.	Feb 2009	B2
7515276	Froggatt et al.	Apr 2009	B2
7527594	Vardi et al.	May 2009	B2
7534251	Wasdyke	May 2009	B2
7535797	Peng et al.	May 2009	B2
7547304	Johnson	Jun 2009	B2
7564949	Sattler et al.	Jul 2009	B2
7577471	Camus et al.	Aug 2009	B2
7583857	Xu et al.	Sep 2009	B2
7603165	Townsend et al.	Oct 2009	B2
7612773	Magnin et al.	Nov 2009	B2
7633627	Choma et al.	Dec 2009	B2
7645229	Armstrong	Jan 2010	B2
7658715	Park et al.	Feb 2010	B2
7660452	Zwirn et al.	Feb 2010	B2
7660492	Bates et al.	Feb 2010	B2
7666204	Thornton et al.	Feb 2010	B2
7672790	McGraw et al.	Mar 2010	B2
7680247	Atzinger et al.	Mar 2010	B2
7684991	Stohr et al.	Mar 2010	B2
7711413	Feldman et al.	May 2010	B2
7720322	Prisco	May 2010	B2
7728986	Lasker et al.	Jun 2010	B2
7734009	Brunner et al.	Jun 2010	B2
7736317	Stephens et al.	Jun 2010	B2
7742795	Stone et al.	Jun 2010	B2
7743189	Brown et al.	Jun 2010	B2
7762954	Nix et al.	Jul 2010	B2
7766896	Kornkven Volk et al.	Aug 2010	B2
7773792	Kimmel et al.	Aug 2010	B2
7775981	Guracar et al.	Aug 2010	B1
7777399	Eidenschink et al.	Aug 2010	B2
7781724	Childers et al.	Aug 2010	B2
7783337	Feldman et al.	Aug 2010	B2
7787127	Galle et al.	Aug 2010	B2
7792342	Barbu et al.	Sep 2010	B2
7801343	Unal et al.	Sep 2010	B2
7801590	Feldman et al.	Sep 2010	B2
7813609	Petersen et al.	Oct 2010	B2
7831081	Li	Nov 2010	B2
7846101	Eberle et al.	Dec 2010	B2
7853104	Oota et al.	Dec 2010	B2
7853316	Milner et al.	Dec 2010	B2
7860555	Saadat	Dec 2010	B2
7862508	Davies et al.	Jan 2011	B2
7872759	Tearney et al.	Jan 2011	B2
7880868	Aoki	Feb 2011	B2
7881763	Brauker et al.	Feb 2011	B2
7909844	Alkhatib et al.	Mar 2011	B2
7921854	Hennings et al.	Apr 2011	B2
7927784	Simpson	Apr 2011	B2
7929148	Kemp	Apr 2011	B2
7930014	Huennekens et al.	Apr 2011	B2
7930104	Baker et al.	Apr 2011	B2
7936462	Jiang et al.	May 2011	B2
7942852	Mas et al.	May 2011	B2
7947012	Spurchise et al.	May 2011	B2
7951186	Eidenschink et al.	May 2011	B2
7952719	Brennan, III	May 2011	B2
7972353	Hendriksen et al.	Jul 2011	B2
7976492	Brauker et al.	Jul 2011	B2
7977950	Maslen	Jul 2011	B2
7978916	Klingensmith et al.	Jul 2011	B2
7981041	McGahan	Jul 2011	B2
7981151	Rowe	Jul 2011	B2
7983737	Feldman et al.	Jul 2011	B2
7993333	Oral et al.	Aug 2011	B2
7995210	Tearney et al.	Aug 2011	B2
7996060	Trofimov et al.	Aug 2011	B2
7999938	Wang	Aug 2011	B2
8021377	Eskuri	Sep 2011	B2
8021420	Dolan	Sep 2011	B2
8036732	Milner	Oct 2011	B2
8040586	Smith et al.	Oct 2011	B2
8047996	Goodnow et al.	Nov 2011	B2
8049900	Kemp et al.	Nov 2011	B2
8050478	Li et al.	Nov 2011	B2
8050523	Younge et al.	Nov 2011	B2
8052605	Muller et al.	Nov 2011	B2
8057394	Dala-Krishna	Nov 2011	B2
8059923	Bates et al.	Nov 2011	B2
8070800	Lock et al.	Dec 2011	B2
8080800	Hoctor et al.	Dec 2011	B2
8088102	Adams et al.	Jan 2012	B2
8100838	Wright et al.	Jan 2012	B2
8104479	Glynn et al.	Jan 2012	B2
8108030	Castella et al.	Jan 2012	B2
8114102	Galdonik et al.	Feb 2012	B2
8116605	Petersen et al.	Feb 2012	B2
8125648	Milner et al.	Feb 2012	B2
8126239	Sun et al.	Feb 2012	B2
8133199	Weber et al.	Mar 2012	B2
8133269	Flechsenhar et al.	Mar 2012	B2
8140708	Zaharia et al.	Mar 2012	B2
8148877	Jiang et al.	Apr 2012	B2
8167932	Bourang et al.	May 2012	B2
8172757	Jaffe et al.	May 2012	B2
8177809	Mavani et al.	May 2012	B2
8187191	Hancock et al.	May 2012	B2
8187267	Pappone et al.	May 2012	B2
8187830	Hu et al.	May 2012	B2
8199218	Lee et al.	Jun 2012	B2
8206429	Gregorich et al.	Jun 2012	B2
8208995	Tearney et al.	Jun 2012	B2
8222906	Wyar et al.	Jul 2012	B2
8233681	Aylward et al.	Jul 2012	B2
8233718	Klingensmith et al.	Jul 2012	B2
8238624	Doi et al.	Aug 2012	B2
8239938	Simeral et al.	Aug 2012	B2
8277386	Ahmed et al.	Oct 2012	B2
8280470	Milner et al.	Oct 2012	B2
8289284	Glynn et al.	Oct 2012	B2
8289522	Tearney et al.	Oct 2012	B2
8298147	Huennekens et al.	Oct 2012	B2
8298149	Hastings et al.	Oct 2012	B2
8301000	Sillard et al.	Oct 2012	B2
8309428	Lemmerhirt et al.	Nov 2012	B2
8317713	Davies et al.	Nov 2012	B2
8323201	Towfiq et al.	Dec 2012	B2
8329053	Martin et al.	Dec 2012	B2
8336643	Harleman	Dec 2012	B2
8349000	Schreck	Jan 2013	B2
8353945	Andreas et al.	Jan 2013	B2
8353954	Cai et al.	Jan 2013	B2
8357981	Martin et al.	Jan 2013	B2
8361097	Patel et al.	Jan 2013	B2
8386560	Ma et al.	Feb 2013	B2
8398591	Mas et al.	Mar 2013	B2
8412312	Judell et al.	Apr 2013	B2
8417491	Trovato et al.	Apr 2013	B2
8449465	Nair et al.	May 2013	B2
8454685	Hariton et al.	Jun 2013	B2
8454686	Alkhatib	Jun 2013	B2
8475522	Jimenez et al.	Jul 2013	B2
8478384	Schmitt et al.	Jul 2013	B2
8486062	Belhe et al.	Jul 2013	B2
8486063	Werneth et al.	Jul 2013	B2
8491567	Magnin et al.	Jul 2013	B2
8500798	Rowe et al.	Aug 2013	B2
8550911	Sylla	Oct 2013	B2
8594757	Boppart et al.	Nov 2013	B2
8597349	Alkhatib	Dec 2013	B2
8600477	Beyar et al.	Dec 2013	B2
8600917	Schimert et al.	Dec 2013	B1
8601056	Lauwers et al.	Dec 2013	B2
8620055	Barratt et al.	Dec 2013	B2
8644910	Rousso et al.	Feb 2014	B2
9314584	Riley	Apr 2016	B1
20010007940	Tu et al.	Jul 2001	A1
20010029337	Pantages et al.	Oct 2001	A1
20010037073	White et al.	Nov 2001	A1
20010046345	Snyder et al.	Nov 2001	A1
20010049548	Vardi et al.	Dec 2001	A1
20020034276	Hu et al.	Mar 2002	A1
20020041723	Ronnekleiv et al.	Apr 2002	A1
20020069676	Kopp, II et al.	Jun 2002	A1
20020089335	Williams	Jul 2002	A1
20020099289	Crowley	Jul 2002	A1
20020163646	Anderson	Nov 2002	A1
20020186818	Arnaud et al.	Dec 2002	A1
20020196446	Roth et al.	Dec 2002	A1
20020197456	Pope	Dec 2002	A1
20030004412	Izatt et al.	Jan 2003	A1
20030016604	Hanes	Jan 2003	A1
20030018273	Corl et al.	Jan 2003	A1
20030023153	Izatt et al.	Jan 2003	A1
20030032886	Dgany et al.	Feb 2003	A1
20030050871	Broughton	Mar 2003	A1
20030065371	Satake	Apr 2003	A1
20030069723	Hegde	Apr 2003	A1
20030077043	Hamm et al.	Apr 2003	A1
20030085635	Davidsen	May 2003	A1
20030090753	Takeyama et al.	May 2003	A1
20030092995	Thompson	May 2003	A1
20030093059	Griffin et al.	May 2003	A1
20030103212	Westphal et al.	Jun 2003	A1
20030152259	Belykh et al.	Aug 2003	A1
20030181802	Ogawa	Sep 2003	A1
20030187369	Lewis et al.	Oct 2003	A1
20030194165	Silberberg et al.	Oct 2003	A1
20030195419	Harada	Oct 2003	A1
20030208116	Liang et al.	Nov 2003	A1
20030212491	Mitchell et al.	Nov 2003	A1
20030219202	Loeb et al.	Nov 2003	A1
20030220749	Chen et al.	Nov 2003	A1
20030228039	Green	Dec 2003	A1
20040015065	Panescu et al.	Jan 2004	A1
20040023317	Motamedi et al.	Feb 2004	A1
20040028333	Lomas	Feb 2004	A1
20040037742	Jen et al.	Feb 2004	A1
20040042066	Kinoshita et al.	Mar 2004	A1
20040054287	Stephens	Mar 2004	A1
20040067000	Bates et al.	Apr 2004	A1
20040068161	Couvillon	Apr 2004	A1
20040082844	Vardi et al.	Apr 2004	A1
20040092830	Scott et al.	May 2004	A1
20040106853	Moriyama	Jun 2004	A1
20040111552	Arimilli et al.	Jun 2004	A1
20040126048	Dave et al.	Jul 2004	A1
20040143160	Couvillon	Jul 2004	A1
20040146546	Gravett et al.	Jul 2004	A1
20040186369	Lam	Sep 2004	A1
20040186558	Pavcnik et al.	Sep 2004	A1
20040195512	Crosetto	Oct 2004	A1
20040220606	Goshgarian	Nov 2004	A1
20040225220	Rich	Nov 2004	A1
20040239938	Izatt	Dec 2004	A1
20040242990	Brister et al.	Dec 2004	A1
20040248439	Gernhardt et al.	Dec 2004	A1
20040260236	Manning et al.	Dec 2004	A1
20050013778	Green et al.	Jan 2005	A1
20050031176	Hertel et al.	Feb 2005	A1
20050036150	Izatt et al.	Feb 2005	A1
20050078317	Law et al.	Apr 2005	A1
20050101859	Maschke	May 2005	A1
20050140582	Lee et al.	Jun 2005	A1
20050140682	Sumanaweera et al.	Jun 2005	A1
20050140981	Waelti	Jun 2005	A1
20050140984	Hitzenberger	Jun 2005	A1
20050147303	Zhou et al.	Jul 2005	A1
20050165439	Weber et al.	Jul 2005	A1
20050171433	Boppart et al.	Aug 2005	A1
20050171438	Chen et al.	Aug 2005	A1
20050182297	Gravenstein et al.	Aug 2005	A1
20050196028	Kleen et al.	Sep 2005	A1
20050197585	Brockway et al.	Sep 2005	A1
20050203434	Kassab	Sep 2005	A1
20050213103	Everett et al.	Sep 2005	A1
20050215942	Abrahamson et al.	Sep 2005	A1
20050234445	Conquergood et al.	Oct 2005	A1
20050243322	Lasker et al.	Nov 2005	A1
20050249391	Kimmel et al.	Nov 2005	A1
20050251567	Ballew et al.	Nov 2005	A1
20050254059	Alphonse	Nov 2005	A1
20050264823	Zhu et al.	Dec 2005	A1
20060013523	Childlers et al.	Jan 2006	A1
20060015126	Sher	Jan 2006	A1
20060029634	Berg et al.	Feb 2006	A1
20060036167	Shina	Feb 2006	A1
20060038115	Maas	Feb 2006	A1
20060039004	de Boer et al.	Feb 2006	A1
20060041180	Viswanathan et al.	Feb 2006	A1
20060045536	Arahira	Mar 2006	A1
20060055936	Yun et al.	Mar 2006	A1
20060058622	Tearney et al.	Mar 2006	A1
20060064009	Webler et al.	Mar 2006	A1
20060067620	Shishkov et al.	Mar 2006	A1
20060072808	Grimm et al.	Apr 2006	A1
20060074442	Noriega et al.	Apr 2006	A1
20060098927	Schmidt et al.	May 2006	A1
20060100694	Globerman	May 2006	A1
20060106375	Werneth et al.	May 2006	A1
20060132790	Gutin	Jun 2006	A1
20060135870	Webler	Jun 2006	A1
20060142703	Carter et al.	Jun 2006	A1
20060142733	Forsberg	Jun 2006	A1
20060173299	Romley et al.	Aug 2006	A1
20060179255	Yamazaki	Aug 2006	A1
20060184048	Saadat	Aug 2006	A1
20060187537	Huber et al.	Aug 2006	A1
20060195269	Yeatman et al.	Aug 2006	A1
20060204119	Feng et al.	Sep 2006	A1
20060229591	Lee	Oct 2006	A1
20060239312	Kewitsch et al.	Oct 2006	A1
20060241342	Macaulay et al.	Oct 2006	A1
20060241465	Huennekens et al.	Oct 2006	A1
20060241503	Schmitt et al.	Oct 2006	A1
20060244973	Yun et al.	Nov 2006	A1
20060258895	Maschke	Nov 2006	A1
20060264743	Kleen et al.	Nov 2006	A1
20060267756	Kates	Nov 2006	A1
20060270976	Savage et al.	Nov 2006	A1
20060276709	Khamene et al.	Dec 2006	A1
20060279742	Tearney et al.	Dec 2006	A1
20060279743	Boesser et al.	Dec 2006	A1
20060285638	Boese et al.	Dec 2006	A1
20060287595	Maschke	Dec 2006	A1
20060293597	Johnson et al.	Dec 2006	A1
20070015969	Feldman et al.	Jan 2007	A1
20070016029	Donaldson et al.	Jan 2007	A1
20070016034	Donaldson	Jan 2007	A1
20070016062	Park et al.	Jan 2007	A1
20070027390	Maschke et al.	Feb 2007	A1
20070036417	Argiro et al.	Feb 2007	A1
20070038061	Huennekens et al.	Feb 2007	A1
20070038121	Feldman et al.	Feb 2007	A1
20070038125	Kleen et al.	Feb 2007	A1
20070043292	Camus et al.	Feb 2007	A1
20070043597	Donaldson	Feb 2007	A1
20070049847	Osborne	Mar 2007	A1
20070060973	Ludvig et al.	Mar 2007	A1
20070065077	Childers et al.	Mar 2007	A1
20070066888	Maschke	Mar 2007	A1
20070066890	Maschke	Mar 2007	A1
20070066983	Maschke	Mar 2007	A1
20070084995	Newton et al.	Apr 2007	A1
20070100226	Yankelevitz et al.	May 2007	A1
20070135887	Maschke	Jun 2007	A1
20070142707	Wiklof et al.	Jun 2007	A1
20070156019	Larkin et al.	Jul 2007	A1
20070161893	Milner et al.	Jul 2007	A1
20070161896	Adachi et al.	Jul 2007	A1
20070161963	Smalling	Jul 2007	A1
20070162860	Muralidharan et al.	Jul 2007	A1
20070165141	Srinivas et al.	Jul 2007	A1
20070167710	Unal et al.	Jul 2007	A1
20070167804	Park et al.	Jul 2007	A1
20070191682	Rolland et al.	Aug 2007	A1
20070201736	Klingensmith et al.	Aug 2007	A1
20070206193	Pesach	Sep 2007	A1
20070208276	Kornkven Volk et al.	Sep 2007	A1
20070225220	Ming et al.	Sep 2007	A1
20070225590	Ramos	Sep 2007	A1
20070229801	Tearney et al.	Oct 2007	A1
20070232872	Prough et al.	Oct 2007	A1
20070232874	Ince	Oct 2007	A1
20070232890	Hirota	Oct 2007	A1
20070232891	Hirota	Oct 2007	A1
20070232892	Hirota	Oct 2007	A1
20070232893	Tanioka	Oct 2007	A1
20070232933	Gille et al.	Oct 2007	A1
20070238957	Yared	Oct 2007	A1
20070247033	Eidenschink et al.	Oct 2007	A1
20070250000	Magnin et al.	Oct 2007	A1
20070250036	Volk et al.	Oct 2007	A1
20070258094	Izatt et al.	Nov 2007	A1
20070260138	Feldman et al.	Nov 2007	A1
20070278389	Ajgaonkar et al.	Dec 2007	A1
20070287914	Cohen	Dec 2007	A1
20080002183	Yatagai et al.	Jan 2008	A1
20080013093	Izatt et al.	Jan 2008	A1
20080021275	Tearney et al.	Jan 2008	A1
20080027481	Gilson et al.	Jan 2008	A1
20080043024	Schiwietz et al.	Feb 2008	A1
20080045842	Furnish	Feb 2008	A1
20080051660	Kakadaris et al.	Feb 2008	A1
20080063304	Russak et al.	Mar 2008	A1
20080085041	Breeuwer	Apr 2008	A1
20080095465	Mullick et al.	Apr 2008	A1
20080095714	Castella et al.	Apr 2008	A1
20080097194	Milner	Apr 2008	A1
20080101667	Begelman et al.	May 2008	A1
20080108867	Zhou	May 2008	A1
20080114254	Matcovitch et al.	May 2008	A1
20080119739	Vardi et al.	May 2008	A1
20080124495	Horn et al.	May 2008	A1
20080125772	Stone et al.	May 2008	A1
20080139897	Ainsworth et al.	Jun 2008	A1
20080143707	Mitchell	Jun 2008	A1
20080146941	Dala-Krishna	Jun 2008	A1
20080147111	Johnson et al.	Jun 2008	A1
20080154128	Milner	Jun 2008	A1
20080161696	Schmitt et al.	Jul 2008	A1
20080171944	Brenneman et al.	Jul 2008	A1
20080175465	Jiang et al.	Jul 2008	A1
20080177183	Courtney et al.	Jul 2008	A1
20080180683	Kemp	Jul 2008	A1
20080181477	Izatt et al.	Jul 2008	A1
20080187201	Liang et al.	Aug 2008	A1
20080228086	Ilegbusi et al.	Sep 2008	A1
20080247622	Aylward et al.	Oct 2008	A1
20080247716	Thomas et al.	Oct 2008	A1
20080262470	Lee et al.	Oct 2008	A1
20080262489	Steinke	Oct 2008	A1
20080269599	Csavoy et al.	Oct 2008	A1
20080281205	Naghavi et al.	Nov 2008	A1
20080281248	Angheloiu et al.	Nov 2008	A1
20080285043	Fercher et al.	Nov 2008	A1
20080287795	Klingensmith et al.	Nov 2008	A1
20080291463	Milner et al.	Nov 2008	A1
20080292173	Hsieh et al.	Nov 2008	A1
20080294034	Krueger et al.	Nov 2008	A1
20080298655	Edwards	Dec 2008	A1
20080306766	Ozeki et al.	Dec 2008	A1
20090009801	Tabuki	Jan 2009	A1
20090018393	Dick et al.	Jan 2009	A1
20090034813	Dikmen et al.	Feb 2009	A1
20090043191	Castella et al.	Feb 2009	A1
20090046295	Kemp et al.	Feb 2009	A1
20090052614	Hempel et al.	Feb 2009	A1
20090069843	Agnew	Mar 2009	A1
20090079993	Yatagai et al.	Mar 2009	A1
20090088650	Corl	Apr 2009	A1
20090093980	Kemp et al.	Apr 2009	A1
20090122320	Petersen et al.	May 2009	A1
20090138544	Wegenkittl et al.	May 2009	A1
20090149739	Maschke	Jun 2009	A9
20090156941	Moore	Jun 2009	A1
20090174886	Inoue	Jul 2009	A1
20090174931	Huber et al.	Jul 2009	A1
20090177090	Grunwald et al.	Jul 2009	A1
20090177183	Pinkernell et al.	Jul 2009	A1
20090195514	Glynn et al.	Aug 2009	A1
20090196470	Carl et al.	Aug 2009	A1
20090198125	Nakabayashi et al.	Aug 2009	A1
20090203991	Papaioannou et al.	Aug 2009	A1
20090264768	Courtney et al.	Oct 2009	A1
20090264770	Liu	Oct 2009	A1
20090269014	Winberg et al.	Oct 2009	A1
20090270695	McEowen	Oct 2009	A1
20090284322	Harrison et al.	Nov 2009	A1
20090284332	Moore et al.	Nov 2009	A1
20090284749	Johnson et al.	Nov 2009	A1
20090290167	Flanders et al.	Nov 2009	A1
20090292048	Li et al.	Nov 2009	A1
20090299195	Muller et al.	Dec 2009	A1
20090299284	Holman et al.	Dec 2009	A1
20090318951	Kashkarov et al.	Dec 2009	A1
20090326634	Vardi	Dec 2009	A1
20100007669	Bethune et al.	Jan 2010	A1
20100023033	Mauch	Jan 2010	A1
20100030042	Denninghoff et al.	Feb 2010	A1
20100061611	Xu et al.	Mar 2010	A1
20100063400	Hall et al.	Mar 2010	A1
20100087732	Eberle et al.	Apr 2010	A1
20100094125	Younge et al.	Apr 2010	A1
20100094127	Xu	Apr 2010	A1
20100094135	Fang-Yen et al.	Apr 2010	A1
20100094143	Mahapatra et al.	Apr 2010	A1
20100113919	Maschke	May 2010	A1
20100125238	Lye et al.	May 2010	A1
20100125268	Gustus et al.	May 2010	A1
20100125648	Zaharia et al.	May 2010	A1
20100128348	Taverner	May 2010	A1
20100152717	Keeler	Jun 2010	A1
20100160788	Davies et al.	Jun 2010	A1
20100161023	Cohen et al.	Jun 2010	A1
20100168714	Burke et al.	Jul 2010	A1
20100179421	Tupin	Jul 2010	A1
20100179426	Davies et al.	Jul 2010	A1
20100220334	Condit et al.	Sep 2010	A1
20100226607	Zhang et al.	Sep 2010	A1
20100234698	Manstrom	Sep 2010	A1
20100234736	Corl	Sep 2010	A1
20100249601	Courtney	Sep 2010	A1
20100256616	Katoh et al.	Oct 2010	A1
20100272432	Johnson	Oct 2010	A1
20100284590	Peng et al.	Nov 2010	A1
20100290693	Cohen et al.	Nov 2010	A1
20100331950	Strommer	Dec 2010	A1
20110010925	Nix et al.	Jan 2011	A1
20110021926	Spencer et al.	Jan 2011	A1
20110025853	Richardson	Feb 2011	A1
20110026797	Declerck et al.	Feb 2011	A1
20110032533	Izatt et al.	Feb 2011	A1
20110034801	Baumgart	Feb 2011	A1
20110044546	Pan et al.	Feb 2011	A1
20110066073	Kuiper et al.	Mar 2011	A1
20110071401	Hastings et al.	Mar 2011	A1
20110072405	Chen et al.	Mar 2011	A1
20110077528	Kemp et al.	Mar 2011	A1
20110080591	Johnson et al.	Apr 2011	A1
20110087104	Moore et al.	Apr 2011	A1
20110137140	Tearney et al.	Jun 2011	A1
20110144502	Zhou et al.	Jun 2011	A1
20110152771	Milner et al.	Jun 2011	A1
20110157597	Lu et al.	Jun 2011	A1
20110160586	Li et al.	Jun 2011	A1
20110178413	Schmitt et al.	Jul 2011	A1
20110190586	Kemp	Aug 2011	A1
20110216378	Poon et al.	Sep 2011	A1
20110220985	Son et al.	Sep 2011	A1
20110238061	van der Weide et al.	Sep 2011	A1
20110238083	Moll et al.	Sep 2011	A1
20110245669	Zhang	Oct 2011	A1
20110249094	Wang et al.	Oct 2011	A1
20110257545	Suri	Oct 2011	A1
20110264125	Wilson et al.	Oct 2011	A1
20110274329	Mathew et al.	Nov 2011	A1
20110282334	Groenhoff	Nov 2011	A1
20110301684	Fischell et al.	Dec 2011	A1
20110306995	Moberg	Dec 2011	A1
20110319752	Steinberg et al.	Dec 2011	A1
20120004529	Tolkowsky et al.	Jan 2012	A1
20120004668	Wallace et al.	Jan 2012	A1
20120013914	Kemp et al.	Jan 2012	A1
20120016344	Kusakabe	Jan 2012	A1
20120016395	Olson	Jan 2012	A1
20120022360	Kemp	Jan 2012	A1
20120026503	Lewandowski et al.	Feb 2012	A1
20120029007	Graham et al.	Feb 2012	A1
20120059253	Wang et al.	Mar 2012	A1
20120059368	Takaoka et al.	Mar 2012	A1
20120062843	Ferguson et al.	Mar 2012	A1
20120065481	Hunter et al.	Mar 2012	A1
20120071823	Chen	Mar 2012	A1
20120071838	Fojtik	Mar 2012	A1
20120075638	Rollins et al.	Mar 2012	A1
20120083696	Kitamura	Apr 2012	A1
20120095340	Smith	Apr 2012	A1
20120095372	Sverdlik et al.	Apr 2012	A1
20120108943	Bates et al.	May 2012	A1
20120113108	Dala-Krishna	May 2012	A1
20120116353	Arnold et al.	May 2012	A1
20120130243	Balocco et al.	May 2012	A1
20120130247	Waters et al.	May 2012	A1
20120136259	Milner et al.	May 2012	A1
20120136427	Palmaz et al.	May 2012	A1
20120137075	Vorbach	May 2012	A1
20120155734	Barratt et al.	Jun 2012	A1
20120158101	Stone et al.	Jun 2012	A1
20120162660	Kemp	Jun 2012	A1
20120165661	Kemp et al.	Jun 2012	A1
20120170848	Kemp et al.	Jul 2012	A1
20120172698	Teo et al.	Jul 2012	A1
20120176607	Ott	Jul 2012	A1
20120184853	Waters	Jul 2012	A1
20120184859	Shah et al.	Jul 2012	A1
20120184977	Wolf	Jul 2012	A1
20120215094	Rahimian et al.	Aug 2012	A1
20120220836	Alpert et al.	Aug 2012	A1
20120220851	Razansky et al.	Aug 2012	A1
20120220865	Brown et al.	Aug 2012	A1
20120220874	Hancock et al.	Aug 2012	A1
20120220883	Manstrom et al.	Aug 2012	A1
20120224751	Kemp et al.	Sep 2012	A1
20120226153	Brown et al.	Sep 2012	A1
20120230565	Steinberg et al.	Sep 2012	A1
20120232400	Dickinson et al.	Sep 2012	A1
20120238869	Schmitt et al.	Sep 2012	A1
20120238956	Yamada et al.	Sep 2012	A1
20120244043	Leblanc et al.	Sep 2012	A1
20120250028	Schmitt et al.	Oct 2012	A1
20120253186	Simpson et al.	Oct 2012	A1
20120253192	Cressman	Oct 2012	A1
20120253276	Govari et al.	Oct 2012	A1
20120257210	Whitney et al.	Oct 2012	A1
20120262720	Brown et al.	Oct 2012	A1
20120265077	Gille et al.	Oct 2012	A1
20120265268	Blum et al.	Oct 2012	A1
20120265296	McNamara et al.	Oct 2012	A1
20120271170	Emelianov et al.	Oct 2012	A1
20120271175	Moore et al.	Oct 2012	A1
20120271339	O'Beirne et al.	Oct 2012	A1
20120274338	Baks et al.	Nov 2012	A1
20120276390	Ji et al.	Nov 2012	A1
20120277722	Gerber et al.	Nov 2012	A1
20120279764	Jiang et al.	Nov 2012	A1
20120283758	Miller et al.	Nov 2012	A1
20120289987	Wilson et al.	Nov 2012	A1
20120299439	Huang	Nov 2012	A1
20120310081	Adler et al.	Dec 2012	A1
20120310332	Murray et al.	Dec 2012	A1
20120319535	Dausch	Dec 2012	A1
20120323075	Younge et al.	Dec 2012	A1
20120323127	Boyden et al.	Dec 2012	A1
20120330141	Brown et al.	Dec 2012	A1
20130015975	Huennekens et al.	Jan 2013	A1
20130023762	Huennekens et al.	Jan 2013	A1
20130023763	Huennekens et al.	Jan 2013	A1
20130026655	Lee et al.	Jan 2013	A1
20130030295	Huennekens et al.	Jan 2013	A1
20130030303	Ahmed et al.	Jan 2013	A1
20130030410	Drasler et al.	Jan 2013	A1
20130053949	Pintor et al.	Feb 2013	A1
20130109958	Baumgart et al.	May 2013	A1
20130109959	Baumgart et al.	May 2013	A1
20130137980	Waters et al.	May 2013	A1
20130150716	Stigall et al.	Jun 2013	A1
20130158594	Carrison et al.	Jun 2013	A1
20130218201	Obermiller et al.	Aug 2013	A1
20130218267	Braido et al.	Aug 2013	A1
20130223789	Lee et al.	Aug 2013	A1
20130223798	Jenner et al.	Aug 2013	A1
20130296704	Magnin et al.	Nov 2013	A1
20130303907	Corl	Nov 2013	A1
20130303920	Corl	Nov 2013	A1
20130310698	Judell et al.	Nov 2013	A1
20130331820	Itou et al.	Dec 2013	A1
20130338766	Hastings et al.	Dec 2013	A1
20130339958	Droste et al.	Dec 2013	A1
20140039294	Jiang	Feb 2014	A1
20140180067	Stigall et al.	Jun 2014	A1
20140180128	Corl	Jun 2014	A1
20140200438	Millett et al.	Jul 2014	A1

Foreign Referenced Citations (79)

Number	Date	Country
1041373	Oct 2000	EP
01172637	Jan 2002	EP
2438877	Apr 2012	EP
2280261	Jan 1995	GB
2000-262461	Sep 2000	JP
2000-292260	Oct 2000	JP
2001-125009	May 2001	JP
2001-272331	Oct 2001	JP
2002-374034	Dec 2002	JP
2003-143783	May 2003	JP
2003-172690	Jun 2003	JP
2003-256876	Sep 2003	JP
2003-287534	Oct 2003	JP
2005-274380	Oct 2005	JP
2006-184284	Jul 2006	JP
2006-266797	Oct 2006	JP
2006-313158	Nov 2006	JP
2007-024677	Feb 2007	JP
2009-233001	Oct 2009	JP
2011-56786	Mar 2011	JP
9101156	Feb 1991	WO
9216865	Oct 1992	WO
9306213	Apr 1993	WO
9308829	May 1993	WO
9838907	Sep 1998	WO
9857583	Dec 1998	WO
0011511	Mar 2000	WO
00044296	Aug 2000	WO
0111409	Feb 2001	WO
03062802	Jul 2003	WO
03073950	Sep 2003	WO
2004010856	Feb 2004	WO
2004023992	Mar 2004	WO
2004096049	Nov 2004	WO
2005047813	May 2005	WO
2005106695	Nov 2005	WO
2006029634	Mar 2006	WO
2006037132	Apr 2006	WO
2006039091	Apr 2006	WO
2006061829	Jun 2006	WO
2006068875	Jun 2006	WO
2006111704	Oct 2006	WO
2006119416	Nov 2006	WO
2006121851	Nov 2006	WO
2006130802	Dec 2006	WO
2007002685	Jan 2007	WO
2007025230	Mar 2007	WO
2007045690	Apr 2007	WO
2007058895	May 2007	WO
2007067323	Jun 2007	WO
2007084995	Jul 2007	WO
2008058084	May 2008	WO
2008069991	Jun 2008	WO
2008107905	Sep 2008	WO
2009009799	Jan 2009	WO
2009009801	Jan 2009	WO
2009046431	Apr 2009	WO
2009121067	Oct 2009	WO
2009137704	Nov 2009	WO
201106886	Jan 2011	WO
2011038048	Mar 2011	WO
2011081688	Jul 2011	WO
2012003369	Jan 2012	WO
2012061935	May 2012	WO
2012071388	May 2012	WO
2012087818	Jun 2012	WO
2012098194	Jul 2012	WO
2012109676	Aug 2012	WO
2012130289	Oct 2012	WO
2012154767	Nov 2012	WO
2012155040	Nov 2012	WO
2013033414	Mar 2013	WO
2013033415	Mar 2013	WO
2013033418	Mar 2013	WO
2013033489	Mar 2013	WO
2013033490	Mar 2013	WO
2013033592	Mar 2013	WO
2013126390	Aug 2013	WO
2014109879	Jul 2014	WO

Non-Patent Literature Citations (190)

Entry
Sihan et al., 2008, A novel approach to quantitative analysis of intraluminal optical coherence tomography imaging, Comput. Cardiol:1089-1092.
Siwy et al., 2003, Electro-responsive asymmetric nanopores in polyimide with stable ion-current signal, Applied Physics A: Materials Science & Processing 76:781-785.
Smith et al., 1989, Absolute displacement measurements using modulation of the spectrum of white light in a Michelson interferometer, Applied Optics, 28(16):3339-3342.
Smith, 1997, The Scientist and Engineer's Guide to Digital Signal Processing, California Technical Publishing, San Diego, CA:432-436.
Soller, 2003, Polarization diverse optical frequency domain interferonnetry:All coupler implementation, Bragg Grating, Photosensitivity, and Poling in Glass Waveguides Conference MB4:30-32.
Song et al., 2012, Active tremor cancellation by a “Smart” handheld vitreoretinal microsurgical tool using swept source optical coherence tomography, Optics Express, 20(21):23414-23421.
Stenqvist et al., 1983, Stiffness of central venous catheters, Acta Anaesthesiol Scand., 2:153-157.
Strickland, 1970, Time-Domain Reflectometer Measurements, Tektronix, Beaverton, OR, (107 pages).
Strobl et al., 2009, An Introduction to Recursive Partitioning:Rationale, Application and Characteristics of Classification and Regression Trees, Bagging and Random Forests, Psychol Methods., 14(4):323-348.
Sutcliffe et al., 1986, Dynamics of UV laser ablation of organic polymer surfaces, Journal of Applied Physics, 60 (9):3315-3322.
Suzuki, 2013, A novel guidewire approach for handling acute-angle bifurcations, J Inv Cardiol 25(1):48-54.
Tanimoto et al., 2008, A novel approach for quantitative analysis of intracoronary optical coherence tomography: high inter-observer agreement with computer-assisted contour detection, Cathet Cardiovascular Intervent., 72(2):228-235.
Tearney et al., 1997, In vivo Endoscopic Optical Biopsy with Optical Coherence Tomography, Science, 276:2037-2039.
Tonino et al., 2009, Fractional flow reserve versus angiography for guiding percutaneous coronary intervention, The New England Journal of Medicine, 360:213-224.
Toregeani et al., 2008, Evaluation of hemodialysis arteriovenous fistula maturation by color-flow Doppler ultrasound, J Vasc. Bras. 7(3):203-213.
Translation of Notice of Reason(s) for Refusal dated Apr. 30, 2014, for Japanese Patent Application No. 2011-508677, (5 pages).
Translation of Notice of Reason(s) for Refusal dated May 25, 2012, for Japanese Patent Application No. 2009-536425, (3 pages).
Translation of Notice of Reason(s) for Refusal dated Nov. 22, 2012, for Japanese Patent Application No. 2010-516304, (6 pages).
Traunecker et al., 1991, Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells, EMBO J., 10:3655-3659.
Trolier-McKinstry et. al., 2004, Thin Film Piezoelectric for MEMS, Journal of Electroceramics 12:7-17.
Tuniz et al., 2010, Weaving the invisible thread: design of an optically invisible metamaterial fibre, Optics Express 18(17):18095-18105.
Turk et al., 1991, Eigenfaces for Recognition, Journal of Cognitive Neuroscience 3(1):71-86.
Tuzel et al., 2006, Region Covariance: A Fast Descriptor for Detection and Classification, European Conference on Computer Vision (ECCV).
Urban et al., 2010, Design of a Pressure Sensor Based on Optical Bragg Grating Lateral Deformation, Sensors (Basel), 10(12):11212-11225.
Vakhtin et al., 2003, Common-path interferometer for frequency-domain optical coherence tomography, Applied Optics, 42(34):6953-6958.
Vakoc et al., 2005, Phase-Resolved Optical Frequency Domain Imaging, Optics Express 13(14):5483-5493.
Verhoeyen et al., 1988, Reshaping human antibodies: grafting an antilysozyme activity, Science, 239:1534-1536.
Villard et al., 2002, Use of a blood substitute to determine instantaneous murine right ventricular thickening with optical coherence tomography, Circulation, 105:1843-1849.
Wang et al., 2002, Optimizing the Beam Patten of a Forward-Viewing Ring-Annular Ultrasound Array for Intravascular Imaging, Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, 49(12).
Wang et al., 2006, Multiple biomarkers for the prediction of first major cardiovascular events and death, The New England Journal of Medicine, 355(25):2631-2639.
Wang et al., 2009, Robust Guidewire Tracking in Fluoroscopy, IEEE Conference on Computer Vision and Pattern Recognition—CVPR 2009:691-698.
Wang et al., 2011, In vivo intracardiac optical coherence tomography imaging through percutaneous access: toward image-guided radio-frequency ablation, J. Biomed. Opt. 0001 16(11):110505-1 (3 pages).
Waterhouse et. al., 1993, Combinatorial infection and in vivo recombination: a strategy for making large phage antibody repertoires, Nucleic Acids Res., 21:2265-2266.
Wegener, 2011, 3D Photonic Metamaterials and Invisibility Cloaks: The Method of Making, MEMS 2011, Cancun, Mexico, Jan. 23-27, 2011.
West et al., 1991, Arterial insufficiency in hemodialysis access procedures: correction by banding technique, Transpl Proc 23(2):1838-40.
Wyawahare et al., 2009, Image registration techniques: an overview, International Journal of Signal Processing, Image Processing and Pattern Recognition, 2(3):11-28.
Yaqoob et al., 2006, Methods and application areas of endoscopic optical coherence tomography, J. Biomed. Opt., 11, 063001-1-063001-19.
Yasuno et al., 2004, Polarization-sensitive complex Fourier domain optical coherence tomography for Jones matrix imaging of biological samples, Applied Physics Letters 85(15):3023-3025.
Zhang et al., 2004, Full range polarization-sensitive Fourier domain optical coherence tomography, Optics Express, 12 (24):6033-6039.
Zitova et al., 2003, Image registration methods: A survey. Image and Vision Computing, 21(11):977-1000.
Abdi et al., 2010, Principal component analysis, Wiley Interdisciplinary Reviews: Computational Statistics 2:433-459.
Adler et al., 2007, Phase-Sensitive Optical Coherence Tomography at up to 370,000 Lines Per Second Using Buffered Fourier Domain Mode-Locked Lasers, Optics Letters, 32(6):626-628.
Agresti, 1996, Models for Matched Pairs, Chapter 8, An Introduction to Categorical Data Analysis, Wiley-Interscience A John Wiley & Sons, Inc., Publication, Hoboken, New Jersey.
Akasheh et al., 2004, Development of piezoelectric micromachined ultrasonic transducers, Sensors and Actuators A Physical, 111:275-287.
Amini et al., 1990, Using dynamic programming for solving variational problems in vision, IEEE Transactions on Pattern Analysis and Machine Intelligence, 12(9):855-867.
Bail et al., 1996, Optical coherence tomography with the “Spectral Radar”—Fast optical analysis in volume scatterers by short coherence interferometry, Optics Letters 21(14):1087-1089.
Bain, 2011, Privacy protection and face recognition, Chapter 3, Handbook of Face Recognition, Stan et al., Springer-Verlag.
Barnea et al., 1972, A class of algorithms for fast digital image registration, IEEE Trans. Computers, 21(2):179-186.
Blanchet et al., 1993, Laser Ablation and the Production of Polymer Films, Science, 262(5134):719-721.
Bonnema, 2008, Imaging Tissue Engineered Blood Vessel Mimics with Optical Tomography, College of Optical Sciences dissertation, University of Arizona (252 pages).
Bouma et al., 1999, Power-efficient nonreciprocal interferometer and linear-scanning fiber-optic catheter for optical coherence tomography, Optics Letters, 24(8):531-533.
Breiman, 2001, Random forests, Machine Learning 45:5-32.
Brown, 1992, A survey of image registration techniques, ACM Computing Surveys 24(4):325-376.
Bruining et al., 2009, Intravascular Ultrasound Registration/Integration with Coronary Angiography, Cardiology Clinics, 27(3):531-540.
Brummer, 1997, An euclidean distance measure between covariance matrices of speechcepstra for text-independent speaker recognition, in Proc. South African Symp. Communications and Signal Processing:167-172.
Burr et al., 2005, Searching for the Center of an Ellipse in Proceedings of the 17th Canadian Conference on Computational Geometry:260-263.
Canny, 1986, A computational approach to edge detection, IEEE Trans. Pattern Anal. Mach. Intell. 8:679-698.
Cavalli et al., 2010, Nanosponge formulations as oxygen delivery systems, International Journal of Pharmaceutics 402:254-257.
Choma et al., 2003, Sensitivity Advantage of Swept Source and Fourier Domain Optical Coherence Tomography, Optics Express 11(18):2183-2189.
Clarke et al., 1995, Hypoxia and myocardial ischaemia during peripheral angioplasty, Clinical Radiology, 50(5):301-303.
Collins, 1993, Coronary flow reserve, British Heart Journal 69:279-281.
Communication Mechanisms for Distributed Real-Time Applications, NI Developer Zone, http://zone.ni.eom/devzone/cda/tut/p/id/3105, accessed Jul. 23, 2007.
Cook, 2007, Use and misuse of receiver operating characteristic curve in risk prediction, Circulation 115(7):928-35.
D'Agostino et al., 2001, Validation of the Framingham coronary heart disease prediction score: results of a multiple ethnic group investigation, JAMA 286:180-187.
David et al., 1974, Protein iodination with solid-state lactoperoxidase, Biochemistry 13:1014-1021.
Davies et al., 1985, Plaque fissuring-the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina, British Heart Journal 53:363-373.
Davies et al., 1993, Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content, British Heart Journal 69:377-381.
Deterministic Data Streaming in Distributed Data Acquisition Systems, NI Developer Zone, “What is Developer Zone?”, http://zone.ni.eom/devzone/cda/tut/p/id/3105, accessed Jul. 23, 2007.
Eigenwillig, 2008, K-Space Linear Fourier Domain Mode Locked Laser and Applications for Optical Coherence Tomography, Optics Express 16(12):8916-8937.
Elghanian et al., 1997, Selective colorimetric detection of polynucleotides based on the distance-dependent optical properties of gold nanoparticles, Science, 277(5329):1078-1080.
Ergun et al., 2003, Capacitive Micromachined Ultrasonic Transducers:Theory and Technology, Journal of Aerospace Engineering, 16(2):76-84.
Evans et al., 2006, Optical coherence tomography to identify intramucosa carcinoma and high-grade dysplasia in Barrett's esophagus, Clin Gast Hepat 4(1):38-43.
Fatemi et al., 1999, Vibro-acoustography: an imaging modality based on ultrasound-stimulated scoustic emission, PNAS U.S.A., 96(12):6603-6608.
Felzenszwalb et al., 2005, Pictorial Structures for Object Recognition, International Journal of Computer Vision, 61 (1):55-79.
Ferring et al., 2008, Vasculature ultrasound for the pre-operative evaluation prior to arteriovenous fistula formation for haemodialysis: review of the evidence, Nephrol. Dial. Transplant. 23(6):1809-1815.
Fischler et al., 1973, The representation and matching of pictorial structures, IEEE Transactions on Computer 22:67-92.
Fleming et al., 2010, Real-time monitoring of cardiac radio-frequency ablation lesion formation using an optical coherence tomography forward-imaging catheter, Journal of Biomedical Optics 15 (3):030516-1 (3 pages).
Fookes et al., 2002, Rigid and non-rigid image registration and its association with mutual information:A review, Technical Report ISBN:1 86435 569 7, RCCVA, QUT.
Forstner & Moonen, 1999, A metric for covariance matrices, In Technical Report of the Dpt of Geodesy and Geoinformatics, Stuttgart University, 113-128.
Goel et al., 2006, Minimally Invasive Limited Ligation Endoluminal-assisted Revision (MILLER) for treatment of dialysis access-associated steal syndrome, Kidney Int 70(4):765-70.
Gotzinger et al., 2005, High speed spectral domain polarization sensitive optical coherence tomography of the human retina, Optics Express 13(25):10217-10229.
Gould et al., 1974, Physiologic basis for assessing critical coronary stenosis, American Journal of Cardiology, 33:87-94.
Griffiths et al., 1993, Human anti-self antibodies with high specificity from phage display libraries, The EMBO Journal, 12:725-734.
Griffiths et al., 1994, Isolation of high affinity human antibodies directly from large synthetic repertoires, The EMBO Journal, 13(14):3245-3260.
Grund et al., 2010, Analysis of biomarker data:logs, odds, ratios and ROC curves, Curr Opin HIV AIDS 5(6):473-479.
Harrison et al., 2011, Guidewire Stiffness: What's in a name?, J Endovasc Ther, 18(6):797-801.
Huber et al., 2005, Amplified, Frequency Swept Lasers for Frequency Domain Reflectometry and OCT Imaging: Design and Scaling Principles, Optics Express 13(9):3513-3528.
Huber et al., 2006, Fourier Domain Mode Locking (FDML): A New Laser Operating Regime and Applications for Optical Coherence Tomography, Optics Express 14(8):3225-3237.
International Search Report and Written Opinion dated Mar. 11, 2014, for International Patent Application No. PCT/US13/75675, filed Dec. 17, 2013 (7 pages).
International Search Report and Written Opinion dated Mar. 19, 2014, for International Patent Application No. PCT/US13/075353, filed Dec. 16, 2013 (8 pages).
International Search Report and Written Opinion dated Nov. 2, 2012, for International Patent Application No. PCT/US12/53168, filed Aug. 30, 2013 (8 pages).
International Search Report and Written Opinion dated Apr. 14, 2014, for International Patent Application No. PCT/US2013/076148, filed Dec. 18, 2013 (8 pages).
International Search Report and Written Opinion dated Apr. 21, 2014, for International Patent Application No. PCT/US2013/076015, filed Dec. 18, 2013 (7 pages).
International Search Report and Written Opinion dated Apr. 23, 2014, for International Patent Application No. PCT/US2013/075328, filed Dec. 16, 2013 (8 pages).
International Search Report and Written Opinion dated Apr. 29, 2014, for International Patent Application No. PCT/US13/76093, filed Dec. 18, 2013 (6 pages).
International Search Report and Written Opinion dated Apr. 9, 2014, for International Patent Application No. PCT/US13/75089, filed Dec. 13, 2013 (7 pages).
International Search Report and Written Opinion dated Feb. 21, 2014, for International Patent Application No. PCT/US13/76053, filed Dec. 18, 2013 (9 pages).
International Search Report and Written Opinion dated Feb. 21, 2014, for International Patent Application No. PCT/US2013/076965, filed Dec. 20, 2013 (6 pages).
International Search Report and Written Opinion dated Feb. 27, 2014, for International Patent Application No. PCT/US13/75416, filed Dec. 16, 2013 (7 pages).
International Search Report and Written Opinion dated Feb. 28, 2014, for International Patent Application No. PCT/US13/75653, filed Dec. 17, 2013 (7 pages).
International Search Report and Written Opinion dated Feb. 28, 2014, for International Patent Application No. PCT/US13/75990, filed Dec. 18, 2013 (7 pages).
International Search Report and Written Opinion dated Jan. 16, 2009, for International Patent Application No. PCT/US08/78963 filed on Oct. 6, 2008 (7 pages).
International Search Report and Written Opinion dated Jul. 30, 2014, for International Patent Application No. PCT/US14/21659, filed Mar. 7, 2014 (15 pages).
International Search Report and Written Opinion dated Mar. 10, 2014, for International Patent Application No. PCT/US2013/076212, filed Dec. 18, 2013 (8 pages).
International Search Report and Written Opinion dated Mar. 11, 2014, for International Patent Application No. PCT/US13/76173, filed Dec. 16, 2013 (9 pages).
International Search Report and Written Opinion dated Mar. 11, 2014, for International Patent Application No. PCT/US13/76449, filed Dec. 19, 2013 (9 pages).
International Search Report and Written Opinion dated Mar. 18, 2014, for International Patent Application No. PCT/US2013/076502, filed Dec. 19, 2013 (7 pages).
International Search Report and Written Opinion dated Mar. 18, 2014, for International Patent Application No. PCT/US2013/076788, filed Dec. 20, 2013 (7 pages).
International Search Report and Written Opinion dated Mar. 19, 2014, for International Patent Application No. PCT/US13/75349, filed Dec. 16, 2013 (10 pages).
International Search Report and Written Opinion dated Mar. 19, 2014, for International Patent Application No. PCT/US2013/076587, filed Dec. 19, 2013 (10 pages).
International Search Report and Written Opinion dated Mar. 19, 2014, for International Patent Application No. PCT/US2013/076909, filed Dec. 20, 2013 (7 pages).
International Search Report and Written Opinion dated Mar. 7, 2014, for International Patent Application No. PCT/US2013/076304, filed Dec. 18, 2013 (9 pages).
International Search Report and Written Opinion dated Mar. 7, 2014, for International Patent Application No. PCT/US2013/076480, filed Dec. 19, 2013 (8 pages).
International Search Report and Written Opinion dated Mar. 7, 2014, for International Patent Application No. PCT/US2013/076512, filed Dec. 19, 2013 (8 pages).
International Search Report and Written Opinion dated Mar. 7, 2014, for International Patent Application No. PCT/US2013/076531, filed Dec. 19, 2013 (10 pages).
Jakobovits et al., 1993, Analysis of homozygous mutant chimeric mice:deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production, PNAS USA 90:2551-255.
Jakobovits et al., 1993, Germ-line transmission and expression of a human-derived yeast artificial chromosome, Nature 362:255-258.
Jang et al., 2002, Visualization of Coronary Atherosclerotic Plaques in Patients Using Optical Coherence Tomography: Comparison With Intravascular Ultrasound, Journal of the American College of Cardiology 39:604-609.
Jiang et al., 1992, Image registration of multimodality 3-D medical images by chamfer matching, Proc. SPIE 1660, Biomedical Image Processing and Three-Dimensional Microscopy, 356-366.
Johnson et al., 1993, Human antibody engineering: Current Opinion in Structural Biology, 3:564-571.
Jones et al., 1986, Replacing the complementarity-determining regions in a human antibody with those from a mouse, Nature, 321:522-525.
Juviler et al., 2008, Anorectal sepsis and fistula-in-ano, Surgical Technology International, 17:139-149.
Karapatis et al., 1998, Direct rapid tooling:a review of current research, Rapid Prototyping Journal, 4(2):77-89.
Karp et al., 2009, The benefit of time-of-flight in PET imaging, J Nucl Med 49:462-470.
Kelly et al., 2005, Detection of Vascular Adhesion Molecule-1 Expression Using a Novel Multimodal Nanoparticle, Circulation Research 96:327-336.
Kemp et al., 2005, Depth Resolved Optic Axis Orientation in Multiple Layered Anisotropic Tissues Measured with Enhanced Polarization Sensitive Optical Coherence Tomography, Optics Express 13(12):4507-4518.
Kersey et al., 1991, Polarization insensitive fiber optic Michelson interferometer, Electron. Lett. 27:518-520.
Kheir et al., 2012, Oxygen Gas-Filled Microparticles Provide Intravenous Oxygen Delivery, Science Translational Medicine 4(140):140ra88 (10 pages).
Khuri-Yakub et al., 2011, Capacitive micromachined ultrasonic transducers for medical imaging and therapy, J Micromech Microeng. 21(5):054004-054014.
Kirkman, 1991, Technique for flow reduction in dialysis access fistulas, Surg Gyn Obstet, 172(3):231-3.
Kohler et al., 1975, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, 256:495-7.
Koo et al., 2011, Diagnosis of IschemiaCausing Coronary Stenoses by Noninvasive Fractional Flow Reserve Computed From Coronary Computed Tomographic Angiograms, J Am Coll Cardiol 58(19):1989-1997.
Kozbor et al., 1984, A human hybrid myeloma for production of human monoclonal antibodies, J. Immunol., 133:3001-3005.
Kruth et al., 2003, Lasers and materials in selective laser sintering, Assembly Automation, 23(4):357-371.
Kumagai et al., 1994, Ablation of polymer films by a femtosecond high-peak-power Ti:sapphire laser at 798 nm, Applied Physics Letters, 65(14):1850-1852.
Larin et al., 2002, Noninvasive Blood Glucose Monitoring with Optical Coherence Tomography: a pilot study in human subjects, Diabetes Care, 25(12):2263-7.
Larin et al., 2004, Measurement of Refractive Index Variation of Physiological Analytes using Differential Phase OCT, Proc of SPIE 5325:31-34.
Laufer, 1996, Introduction to Optics and Lasers in Engineering, Cambridge University Press, Cambridge UK:156-162.
Lefevre et al., 2001, Stenting of bifurcation lesions:a rational approach, J. Interv. Cardiol., 14(6):573-585.
Li et al., 2000, Optical Coherence Tomography: Advanced Technology for the Endoscopic Imaging of Barrett's Esophagus, Endoscopy, 32(12):921-930.
Little et al., 1991, The underlying coronary lesion in myocardial infarction:implications for coronary angiography, Clinical Cardiology, 14(11):868-874.
Loo, 2004, Nanoshell Enabled Photonics-Based Imaging and Therapy of Cancer, Technology in Cancer Research & Treatment 3(1):33-40.
Machine translation of JP 2000-097846.
Machine translation of JP 2000-321034.
Machine translation of JP 2000-329534.
Machine translation of JP 2004-004080.
Maintz et al., 1998, An Overview of Medical Image Registration Methods, Technical Report UU-CS, (22 pages).
Mamas et al., 2010, Resting Pd/Pa measured with intracoronary pressure wire strongly predicts fractional flow reserve, Journal of Invasive Cardiology 22(6):260-265.
Marks et al., 1991, By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage, J. Mol. Biol. 222:581-597.
Marks et al., 1992, By-Passing Immunization:Building High Affinity Human Antibodies by Chain Shuffling, BioTechnol., 10:779-783.
Maruno et al., 1991, Fluorine containing optical adhesives for optical communications systems, J. Appl. Polymer. Sci. 42:2141-2148.
McCafferty et al., 1990, Phage antibodies: filamentous phage displaying antibody variable domains, Nature 348:552-554.
Mendieta et al., 1996, Complementary sequence correlations with applications to reflectometry studies, Instrumentation and Development 3(6):37-46.
Mickley, 2008, Steal Syndrome-strategies to preserve vascular access and extremity, Nephrol Dial Transplant 23:19-24.
Miller et al., 2010, The MILLER banding procedure is an effective method for treating dialysis-associated steal syndrome, Kidney International 77:359-366.
Milstein et al., 1983, Hybrid hybridomas and their use in immunohistochemistry, Nature 305:537-540.
Mindlin et al., 1936, A force at a point of a semi-infinite solid, Physics, 7:195-202.
Morrison et al., 1984, Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains, PNAS 81:6851-6855.
Munson et al., 1980, Ligand: a versatile computerized approach for characterization of ligand-binding systems, Analytical Biochemistry, 107:220-239.
Nezam, 2008, High Speed Polygon-Scanner-Based Wavelength-Swept Laser Source in the Telescope-Less Configurations with Application in Optical Coherence Tomography, Optics Letters 33(15):1741-1743.
Nissen, 2001, Coronary Angiography and Intravascular Ultrasound, American Journal of Cardiology, 87 (suppl):15A-20A.
Nitenberg et al., 1995, Coronary vascular reserve in humans: a critical review of methods of evaluation and of interpretation of the results, Eur Heart J. 16(Suppl 1):7-21.
Notice of Reason(s) for Refusal dated Apr. 30, 2013, for Japanese Patent Application No. 2011-508677 for Optical Imaging Catheter for Aberation Balancing to Volcano Corporation, which application is a Japanese national stage entry of PCT/US2009/043181 with international filing date May 7, 2009, of the same title, published on Nov. 12, 2009, as WO 2009/137704, and accompanying English translation of the Notice of Reason(s) for Refusal and machine translations of JP11-56786 and JP2004-290548 (56 pages).
Nygren, 1982, Conjugation of horseradish peroxidase to Fab fragments with different homobifunctional and heterobifunctional cross-linking reagents. A comparative study, J. Histochem. and Cytochem. 30:407-412.
Oesterle et al., 1986, Angioplasty at coronary bifurcations: single-guide, two-wire technique, Cathet Cardiovasc Diagn., 12:57-63.
Okuno et al., 2003, Recent Advances in Optical Switches Using Silica-based PLC Technology, NTT Technical Review 1(7):20-30.
Oldenburg et al., 1998, Nanoengineering of Optical Resonances, Chemical Physics Letters 288:243-247.
Oldenburg et al., 2003, Fast-Fourier-Domain Delay Line for In Vivo Optical Coherence Tomography with a Polygonal Scanner, Applied Optics, 42(22):4606-4611.
Othonos, 1997, Fiber Bragg gratings, Review of Scientific Instruments 68(12):4309-4341.
Owens et al., 2007, A Survey of General-Purpose Computation on Graphics Hardware, Computer Graphics Forum 26 (1):80-113.
Pain et al., 1981, Preparation of protein A-peroxidase mono conjugate using a heterobifunctional reagent, and its use in enzyme immunoassays, J Immunol Methods, 40:219-30.
Park et al., 2005, Real-time fiber-based multi-functional spectral-domain optical coherence tomography at 1.3 um., Optics Express 13(11):3931-3944.
Pasquesi et al., 2006, In vivo detection of exercise induced ultrastructural changes in genetically-altered murine skeletal muscle using polarization-sensitive optical coherence tomography, Optics Express 14(4):1547-1556.
Pepe et al., 2004, Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker, American Journal of Epidemiology 159(9):882-890.
Persson et al., 1985, Acoustic impedance matching of medical ultrasound transducers, Ultrasonics, 23(2):83-89.
Placht et al., 2012, Fast time-of-flight camera based surface registration for radiotherapy patient positioning, Medical Physics 39(1):4-17.
Rabbani et al., 1999, Review: Strategies to achieve coronary arterial plaque stabilization, Cardiovascular Research 41:402-417.
Radvany et al., 2008, Plaque Excision in Management of Lower Extremity Peripheral Arterial Disease with the SilverHawk Atherectomy Catheter, Seminars in Interventional Radiology, 25(1):11-19.
Reddy et al., 1996, An FFT-Based Technique for Translation, Rotation, and Scale-Invariant Image Registration, IEEE Transaction on Image Processing 5(8):1266-1271.
Riechmann et al., 1988, Reshaping human antibodies for therapy, Nature, 332:323-327.
Rivers et al., 1992, Correction of steal syndrome secondary to hemodialysis access fistulas: a simplified quantitative technique, Surgery, 112(3):593-7.
Robbin et al., 2002, Hemodialysis Arteriovenous Fistula Maturity: US Evaluation, Radiology 225:59-64.
Rollins et al., 1998, In vivo video rate optical coherence tomography, Optics Express 3:219-229.
Sarunic et al., 2005, Instantaneous Complex Conjugate Resolved Spectral Domain and Swept-Source OCT Using 3x3 Fiber Couplers, Optics Express 13(3):957-967.
Satiani et al., 2009, Predicted Shortage of Vascular Surgeons in the United States, J. Vascular Surgery 50:946-952.
Schneider et al., 2006, T-banding: A technique for flow reduction of a hyper-functioning arteriovenous fistula, J Vase Surg. 43(2):402-405.
Sen et al., 2012, Development and validation of a new adenosine-independent index of stenosis severity from coronary wave-intensity analysis, Journal of the American College of Cardiology 59(15):1392-1402.
Setta et al., 2005, Soft versus firm embryo transfer catheters for assisted reproduction: a systematic review and meta-analysis, Human Reproduction, 20(11):3114-3121.
Seward et al., 1996, Ultrasound Cardioscopy: Embarking on New Journey, Mayo Clinic Proceedings 71(7):629-635.
Shen et al., 2006, Eigengene-based linear discriminant model for tumor classification using gene expression microarray data, Bioinformatics 22(21):2635-2642.

Related Publications (1)

	Number	Date	Country
	20140236118 A1	Aug 2014	US

Provisional Applications (1)

	Number	Date	Country
	61429058	Dec 2010	US

Continuation in Parts (1)

	Number	Date	Country
Parent	13340120	Dec 2011	US
Child	14266218		US

Deep vein thrombosis therapeutic methods

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

CPC

Field of Search

CPC

International Classifications

Term Extension

Abstract